MPDL3280A (anti-PD-L1) treatment leads to clinical act

Nature

515, 558-562

DOI: 10.1038/nature13904

Citation Report

#	Article	IF	Citations
1	Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. Science, 1978, 202, 975-977.	6.0	185
2	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 220-229.	1.3	10
3	Immune system offers clues to cancer treatment. Nature, 2014, , .	13.7	0
4	Cosmic triangles and black-hole masses. Nature, 2014, 515, 498-499.	13.7	0
5	Antitumour immunity gets a boost. Nature, 2014, 515, 496-498.	13.7	90
6	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515, 563-567.	13.7	4,342
7	New clinical advances in immunotherapy for the treatment of solid tumours. Immunology, 2015, 145, 182-201.	2.0	35
8	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Science, 2015, 106, 945-950.	1.7	78
9	Identification of novel <scp>L</scp>câ€derived <scp>T</scp> helper epitope long peptides applicable for <scp>HLA</scp>â€<scp>A</scp>2⁺ cancer patients as cancer vaccine. Cancer Science, 2015, 106, 1493-1498.	1.7	5
10	Development of 1-N-11C-Methyl-l- and -d-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan. Scientific Reports, 2015, 5, 16417.	1.6	15
11	<scp>ADAP</scp> and <scp>SKAP</scp> 55 deficiency suppresses <scp>PD</scp> â€1 expression in <scp>CD</scp> 8 ⁺ cytotoxic T lymphocytes for enhanced antiâ€tumor immunotherapy. EMBO Molecular Medicine, 2015, 7, 754-769.	3.3	41
12	Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC). , 2015, 3, .		12
13	è§£æ˜Žã€Œé²ã,€ã€Œã,"å…ç–«ç™,æ³•. Nature Digest, 2015, 12, 30-32.	0.0	0
14	Management of muscle-invasive bladder cancer in the elderly. Current Opinion in Urology, 2015, 25, 459-467.	0.9	14
15	Emerging immunotherapies for bladder cancer. Current Opinion in Oncology, 2015, 27, 191-200.	1.1	24
18	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
19	Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. Journal of Negative Results in BioMedicine, 2015, 14, 18.	1.4	2
20	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. Journal of Translational Medicine, 2015, 13, 247.	1.8	57

#	Article	IF	Citations
21	Complexity of FGFR signalling in metastatic urothelial cancer. Journal of Hematology and Oncology, 2015, 8, 119.	6.9	28
22	Gene expression meta-analysis reveals immune response convergence on the IFNÎ³-STAT1-IRF1 axis and adaptive immune resistance mechanisms in lymphoma. Genome Medicine, 2015, 7, 96.	3.6	24
23	Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology, 2015, 45, 1892-1905.	1.6	116
24	Chemotherapy for Invasive Bladder Cancer: Five Simple Rules Learned Over 30 Years. Bladder Cancer, 2015, 1, 3-13.	0.2	9
25	B7-H1/PD-1 Blockade Therapy in Urological Malignancies: Current Status and Future Prospects. Tumori, 2015, 101, 549-554.	0.6	6
26	Options in metastatic urothelial cancer after first-line therapy. Current Opinion in Supportive and Palliative Care, 2015, 9, 255-260.	0.5	3
27	Genetic subtypes of invasive bladder cancer. Current Opinion in Urology, 2015, 25, 449-458.	0.9	35
28	Tumorâ€targeted and immuneâ€targeted monoclonal antibodies: Going from passive to active immunotherapy. Pediatric Blood and Cancer, 2015, 62, 1317-1325.	0.8	13
29	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. Current Opinion in Oncology, 2015, 27, 482-488.	1.1	31
30	Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. Melanoma Research, 2015, 25, 503-509.	0.6	59
31	Immunotherapies for bladder cancer. Current Opinion in Urology, 2015, 25, 586-596.	0.9	17
32	Tumor-Infiltrating Lymphocyte Therapy. Cancer Journal (Sudbury, Mass), 2015, 21, 450-464.	1.0	45
33	Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 2015, 6, 5449-5464.	0.8	424
34	Antiâ€"PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation, 2015, 125, 3384-3391.	3.9	1,112
35	Targeting PD-1/PD-L1 in lung cancer: current perspectives. Lung Cancer: Targets and Therapy, 2015, 6, 55.	1.3	10
36	Immunotherapy for bladder cancer. Research and Reports in Urology, 2015, 7, 65.	0.6	148
37	Immunotherapy and Radiation â€" A New Combined Treatment Approach for Bladder Cancer?. Bladder Cancer, 2015, 1, 15-27.	0.2	19
38	A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review. Case Reports in Oncology, 2015, 8, 530-535.	0.3	2

#	Article	IF	Citations
39	New and Promising Strategies in the Management of Bladder Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 105-112.	1.8	20
40	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516.	2.2	79
41	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses, 2015, 7, 5889-5901.	1.5	19
42	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. Forum on Immunopathological Diseases and Therapeutics, 2015, 6, 7-17.	0.1	82
43	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	1.1	390
44	Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer. PLoS ONE, 2015, 10, e0133552.	1.1	55
45	Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. PLoS ONE, 2015, 10, e0136688.	1.1	56
46	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. OncoTargets and Therapy, 2015, 8, 2949.	1.0	7
47	Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging, 2015, 10, 939.	1.3	44
48	Immunotherapy in Tumors. Deutsches Ärzteblatt International, 2015, 112, 809-15.	0.6	31
49	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519.	0.8	105
50	Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83.	1.8	344
51	High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 2015, 6, 33972-33981.	0.8	159
52	Evolving Immunotherapy Strategies in Urothelial Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e284-e290.	1.8	3
53	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 2015, 372, 2509-2520.	13.9	7,696
54	T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348, 74-80.	6.0	1,735
55	PD-1/PD-L1 inhibitors. Current Opinion in Pharmacology, 2015, 23, 32-38.	1.7	483
56	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology, 2015, 35, 15-22.	2.4	33

#	Article	IF	Citations
57	The path forward. Vaccine, 2015, 33, B60-B63.	1.7	14
58	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clinical Therapeutics, 2015, 37, 764-782.	1.1	469
59	Potential Role for Targeted Therapy in Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 201-215.	0.8	30
60	Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. Journal of Clinical Oncology, 2015, 33, 1993-1994.	0.8	20
61	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 2015, 26, 1488-1493.	0.6	234
62	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. Cancer Immunology, Immunotherapy, 2015, 64, 1095-1108.	2.0	19
63	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Antiâ€“PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunology Research, 2015, 3, 1148-1157.	1.6	391
64	CD103 ⁺ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. Journal of Urology, 2015, 194, 556-562.	0.2	142
65	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research, 2015, 3, 855-863.	1.6	60
66	Immunotherapeutic Advancements for Glioblastoma. Frontiers in Oncology, 2015, 5, 12.	1.3	37
67	Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 2015, 11, 1381-1388.	1.1	10
68	Checkpoint blockade in lymphoma. Hematology American Society of Hematology Education Program, 2015, 2015, 69-73.	0.9	11
69	Pseudoprogression and Immune-Related Response in Solid Tumors. Journal of Clinical Oncology, 2015, 33, 3541-3543.	0.8	720
70	Docetaxel for the treatment of bladder cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1657-1664.	1.9	13
71	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. Cancer Immunology Research, 2015, 3, 1292-1298.	1.6	38
72	Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP10025â€“33 peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma. Biochemical and Biophysical Research Communications, 2015, 468, 46-52.	1.0	4
73	Talimogene laherparepvec in the treatment of melanoma. Expert Opinion on Biological Therapy, 2015, 15, 1517-1530.	1.4	8
74	Checkpoint inhibitors in bladder and renal cancers: results and perspectives. Immunotherapy, 2015, 7, 1259-1271.	1.0	22

#	Article	IF	Citations
75	Immunotherapy for Head and Neck Squamous Cell Carcinoma. Hematology/Oncology Clinics of North America, 2015, 29, 1033-1043.	0.9	30
76	Contemporary Systemic Therapy for Urologic Malignancies in Geriatric Patients. Clinics in Geriatric Medicine, 2015, 31, 645-665.	1.0	1
77	The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports, 2015, 12, 2072-2085.	2.9	47
79	Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma. Lung Cancer Management, 2015, 4, 249-259.	1.5	0
80	The role of inflammation in progression of breast cancer: Friend or foe? (Review). International Journal of Oncology, 2015, 47, 797-805.	1.4	52
81	PD-1â€“PD-L1 axis: efficient checkpoint blockade against cancer. Nature Reviews Clinical Oncology, 2015, 12, 63-63.	12.5	58
82	From the genomic frontier to immunotherapeutics. Nature Reviews Urology, 2015, 12, 74-76.	1.9	4
83	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	1.7	14
84	Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research, 2015, 3, 236-244.	1.6	117
85	Cancer Immunotherapy Scores Again. Cell, 2015, 160, 7-9.	13.5	4
86	Biomarkers in Cancer Immunotherapy. Cancer Cell, 2015, 27, 12-14.	7.7	130
87	Multiple checkpoints on the long road towards cancer immunotherapy. Immunology and Cell Biology, 2015, 93, 323-325.	1.0	9
88	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856.	1.9	1,787
90	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1
91	The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135.	1.4	51
92	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Research, 2015, 75, 3800-3811.	0.4	201
93	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
94	Salvage Systemic Therapy for Advanced Urothelial Carcinoma: On the Cusp of a Sea Change?. Oncologist, 2015, 20, 461-463.	1.9	4

#	Article	IF	Citations
95	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. Journal of Immunology, 2015, 195, 1054-1063.	0.4	34
96	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Annals of Oncology, 2015, 26, 1824-1829.	0.6	184
97	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
99	New advances in genitourinary cancer: evidence gathered in 2014. Cancer and Metastasis Reviews, 2015, 34, 443-464.	2.7	4
100	On Molecular Classification of Bladder Cancer: Out of One, Many. European Urology, 2015, 68, 921-923.	0.9	47
101	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 699-706.	3.4	14
102	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029.	1.6	159
103	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2â^'/â^'IL2RÎ³null Immunodeficient Mice. Cancer Research, 2015, 75, 3466-3478.	0.4	137
104	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?. Current Urology Reports, 2015, 16, 59.	1.0	15
105	T-cell exhaustion in the tumor microenvironment. Cell Death and Disease, 2015, 6, e1792-e1792.	2.7	743
106	Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review. Journal of Controlled Release, 2015, 214, 40-61.	4.8	28
107	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	3.2	27
108	Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature Reviews Cancer, 2015, 15, 457-472.	12.8	576
109	The immunocheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921.	1.4	24
110	The New Era of Cancer Immunotherapy. Advances in Cancer Research, 2015, 128, 1-68.	1.9	41
111	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 2015, 21, 482-491.	3.5	146
112	Development of individualized anti-metastasis strategies by engineering nanomedicines. Chemical Society Reviews, 2015, 44, 6258-6286.	18.7	115
113	In-situ tumor vaccination: Bringing the fight to the tumor. Human Vaccines and Immunotherapeutics, 2015, 11, 1901-1909.	1.4	60

#	Article	IF	Citations
114	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, The, 2015, 16, 908-918.	5.1	1,419
115	2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond. EBioMedicine, 2015, 2, 92-93.	2.7	51
116	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist, 2015, 20, 812-822.	1.9	198
117	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Molecular Therapy, 2015, 23, 1630-1640.	3.7	165
118	Inflammation and cancer: advances and new agents. Nature Reviews Clinical Oncology, 2015, 12, 584-596.	12.5	901
119	Antagonists of PD-1 and PD-L1 in Cancer Treatment. Seminars in Oncology, 2015, 42, 587-600.	0.8	259
120	Greater patient access to immuno-oncology therapiesâ€"what can. Ecancermedicalscience, 2015, 9, ed48.	0.6	1
121	Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer. Urologic Clinics of North America, 2015, 42, 217-224.	0.8	9
122	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. Expert Review of Anticancer Therapy, 2015, 15, 509-523.	1.1	21
123	Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy, 2015, 15, 787-801.	1.4	40
124	PD-L1 Inhibition With MPDL3280A for Solid Tumors. Seminars in Oncology, 2015, 42, 484-487.	0.8	46
125	Toxicities of Immunotherapy for the Practitioner. Journal of Clinical Oncology, 2015, 33, 2092-2099.	0.8	521
126	The future of immune checkpoint therapy. Science, 2015, 348, 56-61.	6.0	3,735
128	Immune checkpoint blockade in hematologic malignancies. Blood, 2015, 125, 3393-3400.	0.6	208
129	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunology Research, 2015, 3, 399-411.	1.6	387
130	Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Research, 2015, 75, 2139-2145.	0.4	1,167
132	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
133	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€"small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756

#	Article	IF	Citations
134	Overcoming T cell exhaustion in infection and cancer. Trends in Immunology, 2015, 36, 265-276.	2.9	856
135	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1.	5.8	134
136	The development of immunotherapy in urothelial bladder cancer. Nature Reviews Clinical Oncology, 2015, 12, 193-194.	12.5	8
137	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 410-420.	0.9	17
138	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17.	1.0	180
139	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
140	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
141	Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 2015, 14, 957-964.	1.0	27
143	MicroRNA control of protein expression noise. Science, 2015, 348, 128-132.	6.0	337
144	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. European Urology, 2015, 68, 267-279.	0.9	204
145	Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treatment Reviews, 2015, 41, 341-353.	3.4	43
146	Synergy of Histone-Deacetylase Inhibitor AR-42 with Cisplatin in Bladder Cancer. Journal of Urology, 2015, 194, 547-555.	0.2	25
147	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. Trends in Immunology, 2015, 36, 198-216.	2.9	121
148	Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?. European Urology, 2015, 68, 280-282.	0.9	4
149	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	7.7	3,266
150	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. Cell, 2015, 161, 205-214.	13.5	1,872
151	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Annals of Oncology, 2015, 26, 2375-2391.	0.6	1,136
153	ImmunothÃ©rapie anticancer : les molÃ©cules immunomodulatrices en dÃ©veloppement clinique. Oncologie, 2015, 17, 379-389.	0.2	0

#	Article	IF	Citations
154	Predictors of clinical response to immunotherapy with or without radiotherapy. Journal of Radiation Oncology, 2015, 4, 339-345.	0.7	17
155	Targeted therapies in bladder cancer: an overview of in vivo research. Nature Reviews Urology, 2015, 12, 681-694.	1.9	63
157	Interferons and the Immunogenic Effects of Cancer Therapy. Trends in Immunology, 2015, 36, 725-737.	2.9	107
158	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 2015, 23, 2341-2348.	1.6	399
159	Toward improved effectiveness of bladder cancer immunotherapy. Immunotherapy, 2015, 7, 1039-1042.	1.0	4
160	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nature Genetics, 2015, 47, 1067-1072.	9.4	354
161	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy, 2015, 7, 777-792.	1.0	18
162	Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. Viral Immunology, 2015, 28, 418-424.	0.6	21
163	Editorial Comment to Maintenance monotherapy with gemcitabine after standard platinumâ€based chemotherapy in patients with advanced urothelial cancer. International Journal of Urology, 2015, 22, 495-495.	0.5	0
164	Frequent PD-L1 expression in testicular germ cell tumors. British Journal of Cancer, 2015, 113, 411-413.	2.9	126
165	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306.	1.1	20
166	Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clinical Cancer Research, 2015, 21, 4514-4524.	3.2	110
167	Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700.	8.2	478
168	Immunological evaluation of peptide vaccination for cancer patients with the HLA â€A26 allele. Cancer Science, 2015, 106, 1257-1263.	1.7	7
169	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treatment Reviews, 2015, 41, 914-924.	3.4	41
170	Immunological hallmarks of stromal cells in the tumour microenvironment. Nature Reviews Immunology, 2015, 15, 669-682.	10.6	850
172	ImmunogÃ©nicitÃ© de la chimiothÃ©rapie. Oncologie, 2015, 17, 345-353.	0.2	0
173	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. Trends in Cancer, 2015, 1, 66-75.	3.8	101

#	Article	IF	Citations
174	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. Therapeutic Advances in Urology, 2015, 7, 312-330.	0.9	34
175	Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer. Medical Oncology, 2015, 32, 235.	1.2	9
177	Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. British Journal of Cancer, 2015, 113, 886-893.	2.9	136
178	The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches. Seminars in Cancer Biology, 2015, 35, 125-132.	4.3	20
179	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	1.0	83
180	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Seminars in Oncology, 2015, 42, 640-655.	0.8	179
181	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. Human Vaccines and Immunotherapeutics, 2015, 11, 1201-1208.	1.4	11
182	Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66.	0.1	151
183	Immunopharmacogenomics. , 2015, , .		3
184	The emerging role of the androgen receptor in bladder cancer. Endocrine-Related Cancer, 2015, 22, R265-R277.	1.6	55
185	Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. Pathobiology, 2015, 82, 212-223.	1.9	46
186	Cancer gene therapy with T cell receptors and chimeric antigen receptors. Current Opinion in Pharmacology, 2015, 24, 113-118.	1.7	30
187	Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. OncoImmunology, 2015, 4, e1040218.	2.1	39
188	PD-L1 expression in small cell lung cancer. European Journal of Cancer, 2015, 51, 1853-1855.	1.3	32
189	Engineering opportunities in cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14467-14472.	3.3	111
190	Landscape of Tumor Antigens in T Cell Immunotherapy. Journal of Immunology, 2015, 195, 5117-5122.	0.4	124
191	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine, 2015, 7, 315ra188.	5.8	261
192	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Reviews, 2015, 41, 868-876.	3.4	358

#	Article	IF	Citations
193	Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?. Nature Reviews Urology, 2015, 12, 61-61.	1.9	5
194	Clinical blockade of PD1 and LAG3 â€" potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
195	Checkpoint parley. Nature Reviews Cancer, 2015, 15, 3-3.	12.8	25
196	Checkpoint parley. Nature Reviews Immunology, 2015, 15, 5-5.	10.6	9
197	Immunotherapy in Colorectal Cancer. , 2016, , .		0
199	19. Translating science into therapy of lymphoma. , 2016, , 379-402.		0
200	Translational Medicine Case Studies and Reports. , 2016, , 135-156.		0
201	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 7, 56233-56240.	0.8	48
202	Checkpoint Inhibitors for Advanced Bladder Cancer. Bladder Cancer, 2016, 2, 473-474.	0.2	2
203	Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. OncoTargets and Therapy, 2016, Volume 9, 6075-6082.	1.0	47
204	Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients. Journal of Hepatocellular Carcinoma, 2017, Volume 4, 11-13.	1.8	9
205	A case report and literature review of primary resistant Hodgkin lymphoma: a response to anti-PD-1 after failure of autologous stem cell transplantation and brentuximab vedotin. OncoTargets and Therapy, 2016, Volume 9, 5781-5789.	1.0	2
206	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. International Journal of Molecular Sciences, 2016, 17, 651.	1.8	20
207	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 2016, 7, 30323-30335.	0.8	297
208	Association ofFusobacterium nucleatumwith immunity and molecular alterations in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 557.	1.4	278
209	Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biology and Medicine, 2016, 13, 194-205.	1.4	17
210	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 3187.	1.0	11
211	T cell Bim levels reflect responses to antiâ€"PD-1 cancer therapy. JCI Insight, 2016, 1, .	2.3	68

#	Article	IF	Citations
212	Biomarkers for Immunotherapy: Current Developments and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e493-e503.	1.8	85
213	Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery. Translational Andrology and Urology, 2016, 5, 735-744.	0.6	43
214	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. Oncotarget, 2016, 7, 37331-37346.	0.8	73
216	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer, 2016, 2, 203-213.	0.2	3
217	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget, 2016, 7, 76565-76576.	0.8	100
218	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. BioMed Research International, 2016, 2016, 1-12.	0.9	19
219	PD-L1 Expression Is Associated with Tumor FOXP3⁺ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. Journal of Cancer, 2016, 7, 784-793.	1.2	125
220	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016, 7, 34341-34355.	0.8	258
221	Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313.	0.9	16
222	The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305.	0.7	63
223	Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?. Gastroenterology Research and Practice, 2016, 2016, 1-11.	0.7	79
224	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 2016, 7, 550.	2.2	409
225	Systemic Immunotherapy for the Treatment of Brain Metastases. Frontiers in Oncology, 2016, 6, 49.	1.3	66
226	Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. Frontiers in Oncology, 2016, 6, 139.	1.3	20
227	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. Frontiers in Oncology, 2016, 6, 165.	1.3	9
228	Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives. International Journal of Molecular Sciences, 2016, 17, 43.	1.8	42
229	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. International Journal of Molecular Sciences, 2016, 17, 1151.	1.8	134
230	The Role of PD-L1 Expression andÂIntratumoral Lymphocytes inÂResponseÂto Perioperative ChemotherapyÂfor Urothelial Carcinoma. Bladder Cancer, 2016, 2, 425-432.	0.2	23

#	Article	IF	Citations
231	Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers. PLoS ONE, 2016, 11, e0165856.	1.1	1
232	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. Journal of Cancer, 2016, 7, 484-489.	1.2	106
233	PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets and Therapy, 2016, Volume 9, 5023-5039.	1.0	558
234	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25.	0.2	29
235	Immune checkpoint blockade therapy for bladder cancer treatment. Investigative and Clinical Urology, 2016, 57, S98.	1.0	26
236	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget, 2016, 7, 10215-10227.	0.8	158
237	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget, 2016, 7, 73068-73079.	0.8	76
238	Complete Response and Fatigue Improvement With the Combined Use of Cyclophosphamide and Quercetin in a Patient With Metastatic Bladder Cancer. Medicine (United States), 2016, 95, e2598.	0.4	14
239	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 96-100.	1.0	5
240	Spectrum of genomic alterations in <scp>FGFR</scp>3: current appraisal of the potential role of <scp>FGFR</scp>3 in advanced urothelial carcinoma. BJU International, 2016, 118, 681-691.	1.3	15
241	Pembrolizumab (Keytruda). Human Vaccines and Immunotherapeutics, 2016, 12, 2777-2789.	1.4	237
242	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. Immunotherapy, 2016, 8, 907-921.	1.0	20
243	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.0	31
244	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 596-603.	1.2	43
245	Immunotherapy advances in uro-genital malignancies. Critical Reviews in Oncology/Hematology, 2016, 105, 52-64.	2.0	19
246	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. Cancer Treatment Reviews, 2016, 48, 61-68.	3.4	102
247	Novel Targets and Their Assessment for Cancer Treatment. , 2016, , 163-180.		0
248	Key signaling pathways in the muscleâ€invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. International Journal of Cancer, 2016, 138, 2562-2569.	2.3	34

#	Article	IF	Citations
249	The current status of checkpoint inhibitors in metastatic bladder cancer. Clinical and Experimental Metastasis, 2016, 33, 629-635.	1.7	11
250	A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 2016, 36, 313-320.	1.0	4
251	Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Cancer Letters, 2016, 380, 424-433.	3.2	80
252	Immunotherapy for genitourinary cancer. Anti-Cancer Drugs, 2016, 27, 585-599.	0.7	4
253	Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. ESMO Open, 2016, 1, e000084.	2.0	9
254	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 219-226.	2.0	6
255	What does PD-L1 positive or negative mean?. Journal of Experimental Medicine, 2016, 213, 2835-2840.	4.2	263
256	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I â€" pre-analytical and analytical validation. , 2016, 4, 76.		155
257	SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clinical and Translational Oncology, 2016, 18, 1197-1205.	1.2	10
258	An ILâ€27/Stat3 axis induces expression of programmed cell death 1 ligands (<scp>PD</scp>â€L1/2) on infiltrating macrophages in lymphoma. Cancer Science, 2016, 107, 1696-1704.	1.7	104
259	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 2016, 167, 1540-1554.e12.	13.5	830
261	Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report. BMC Cancer, 2016, 16, 626.	1.1	4
262	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
263	Biochemistry of Oxidative Stress. , 2016, , .		5
264	FOXA1, GATA3 and PPARÉ£ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports, 2016, 6, 38531.	1.6	112
265	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 2016, 1, e000097.	2.0	82
266	Renal effects of immune checkpoint inhibitors. Nephrology Dialysis Transplantation, 2017, 32, gfw382.	0.4	67
267	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. Journal of Translational Medicine, 2016, 14, 173.	1.8	103

#	Article	IF	Citations
268	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Research, 2016, 26, 469-480.	0.6	30
271	Development of target specific agents for bladder cancer. Expert Review of Precision Medicine and Drug Development, 2016, 1, 361-368.	0.4	1
272	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. Cancer Immunology Research, 2016, 4, 279-288.	1.6	29
273	The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. OncoImmunology, 2016, 5, e1134412.	2.1	135
274	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. OncoImmunology, 2016, 5, e1165377.	2.1	42
275	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. Expert Opinion on Biological Therapy, 2016, 16, 895-901.	1.4	20
276	Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology, 2016, 41, 23-31.	2.4	96
277	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
278	Re: Nephron-sparing Techniques Independently Decrease the Risk of Cardiovascular Events Relative to Radical Nephrectomy in Patients with a T1aâ€“T1b Renal Mass and Normal Preoperative Renal Function. European Urology, 2016, 69, 538.	0.9	1
279	PDL1: The Illusion of an Ideal Biomarker. European Urology Focus, 2016, 1, 269-271.	1.6	11
280	Emerging molecular classifications and therapeutic implications for gastric cancer. Chinese Journal of Cancer, 2016, 35, 49.	4.9	35
281	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	0.5	329
282	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. BioDrugs, 2016, 30, 263-273.	2.2	22
283	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Annals of Oncology, 2016, 27, 1456-1466.	0.6	51
284	Targeting T Cell Co-receptors for Cancer Therapy. Immunity, 2016, 44, 1069-1078.	6.6	418
285	Combinatorial Cancer Immunotherapies. Advances in Immunology, 2016, 130, 251-277.	1.1	107
286	Molecular Drivers of the Nonâ€“T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunology Research, 2016, 4, 563-568.	1.6	293
287	Urothelial carcinoma management in elderly or unfit patients. European Journal of Cancer, Supplement, 2016, 14, 1-20.	2.2	45

#	Article	IF	Citations
288	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 313-341.	9.6	15
289	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular Cancer Therapeutics, 2016, 15, 1746-1756.	1.9	45
290	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504.	0.6	460
291	Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. Journal of Clinical Oncology, 2016, 34, 2165-2171.	0.8	134
292	Les anticorps monoclonaux dirigÃ©s contre les checkpoints immunologiquesÂ: de nouvelles approches dâ€™immunothÃ©rapie en onco-hÃ©matologie. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2016, 4, 5-12.	0.1	4
293	PD-1 Blockade Boosts Radiofrequency Ablationâ€“Elicited Adaptive Immune Responses against Tumor. Clinical Cancer Research, 2016, 22, 1173-1184.	3.2	207
294	Systemic therapy for metastatic bladder cancer in 2016 and beyond. Future Oncology, 2016, 12, 1179-1192.	1.1	5
295	A Feedback Control Model of Comprehensive Therapy for Treating Immunogenic Tumours. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2016, 26, 1650039.	0.7	27
296	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. Therapeutic Advances in Urology, 2016, 8, 203-214.	0.9	9
297	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Annals of Oncology, 2016, 27, 1482-1492.	0.6	765
298	Enhanced antitumor effect of combining TRAIL and MnSOD mediated by CEA-controlled oncolytic adenovirus in lung cancer. Cancer Gene Therapy, 2016, 23, 168-177.	2.2	21
299	Emerging Opportunities and Challenges in Cancer Immunotherapy. Clinical Cancer Research, 2016, 22, 1845-1855.	3.2	242
300	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumor Biology, 2016, 37, 7507-7514.	0.8	40
301	Programming the immune checkpoint to treat hematologic malignancies. Expert Opinion on Investigational Drugs, 2016, 25, 755-770.	1.9	11
302	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. Breast Cancer Research and Treatment, 2016, 157, 117-131.	1.1	18
303	From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discovery Today, 2016, 21, 1027-1036.	3.2	137
304	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Modern Pathology, 2016, 29, 753-763.	2.9	230
305	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 2542-2552.	13.9	1,048

#	Article	IF	Citations
306	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	1.8	122
307	Mass spectrometry-based antigen discovery for cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 9-17.	2.4	165
309	Biomarkers associated with checkpoint inhibitors. Annals of Oncology, 2016, 27, 1199-1206.	0.6	142
310	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. International Immunology, 2016, 28, 373-382.	1.8	143
311	Roles of regulatory T cells in cancer immunity. International Immunology, 2016, 28, 401-409.	1.8	412
312	TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy, 2016, 8, 511-519.	1.0	14
313	The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. Future Oncology, 2016, 12, 1833-1846.	1.1	16
314	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
315	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. Journal of Virology, 2016, 90, 8934-8946.	1.5	69
316	Relationship of tumor PD-L1 expression withEGFRwild-type status and poor prognosis in lung adenocarcinoma. Japanese Journal of Clinical Oncology, 2016, 46, 935-941.	0.6	49
317	Realism and pragmatism in developing an effective chimeric antigen receptor T-cell product for solid cancers. Cytotherapy, 2016, 18, 1382-1392.	0.3	8
318	Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 2016, 40, 130-140.	1.0	24
319	CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia, 2016, 18, 636-646.	2.3	161
320	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian Journal of Urology, 2016, 3, 268-277.	0.5	4
321	Intrinsic subtypes and bladder cancer metastasis. Asian Journal of Urology, 2016, 3, 260-267.	0.5	31
322	Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models. Cancer Immunology, Immunotherapy, 2016, 65, 1511-1522.	2.0	17
324	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	3.4	19
325	Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. Future Oncology, 2016, 12, 2673-2682.	1.1	7

#	Article	IF	Citations
326	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. Haematologica, 2016, 101, 1144-1158.	1.7	6
327	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer, 2016, 16, 744.	1.1	94
329	Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy. BMC Cancer, 2016, 16, 752.	1.1	6
330	Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select. Journal of Clinical Oncology, 2016, 34, 3115-3116.	0.8	16
331	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1490.	3.4	68
332	Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opinion on Emerging Drugs, 2016, 21, 283-300.	1.0	15
333	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. Investigational New Drugs, 2016, 34, 677-684.	1.2	30
334	Genentech's PD-L1 agent approved for bladder cancer. Nature Biotechnology, 2016, 34, 789-790.	9.4	10
335	Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer. Clinical Oncology, 2016, 28, 790-796.	0.6	25
337	Concepts in glioma immunotherapy. Cancer Immunology, Immunotherapy, 2016, 65, 1269-1275.	2.0	52
338	PD-L1 Detection in Tumors Using [⁶⁴Cu]Atezolizumab with PET. Bioconjugate Chemistry, 2016, 27, 2103-2110.	1.8	128
339	Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Science, 2016, 107, 590-600.	1.7	12
340	The immune system and cancer evasion strategies: therapeutic concepts. Journal of Internal Medicine, 2016, 279, 541-562.	2.7	212
341	PDâ€1 Pathway Inhibitors: Immunoâ€Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy, 2016, 36, 317-334.	1.2	82
342	Immunotherapy for bladder cancer: rediscovering an old friend. BJU International, 2016, 117, 721-724.	1.3	0
343	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. Cancer Science, 2016, 107, 107-115.	1.7	28
344	Lymphocyteâ€activation geneâ€3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	1.7	168
345	Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry. Cancer Immunology, Immunotherapy, 2016, 65, 1317-1323.	2.0	21

#	Article	IF	Citations
346	Biennial report on genitourinary cancers. European Journal of Cancer, 2016, 66, 125-130.	1.3	1
347	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunology Research, 2016, 4, 820-822.	1.6	63
348	Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Molecular Cancer, 2016, 15, 55.	7.9	212
349	Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab Journal of Urology Arab Association of Urology, 2016, 14, 183-191.	0.7	72
350	Cancer Immunotherapy byÂCheckpoint Blockade. , 2016, , 561-580.		2
351	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. Annals of Oncology, 2016, 27, 1658-1659.	0.6	3
352	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. Cancer, 2016, 122, 3344-3353.	2.0	288
353	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II â€" clinical validation and regulatory considerations. , 2016, 4, 77.		87
354	B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. Scientific Reports, 2016, 6, 36722.	1.6	36
355	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduction and Targeted Therapy, 2016, 1, 16029.	7.1	53
356	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. European Journal of Cancer, 2016, 67, 66-72.	1.3	90
357	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	2.9	144
358	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research, 2016, 22, 4550-4555.	3.2	73
359	Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy, 2016, 8, 767-774.	1.0	9
360	Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology, 2016, 64, 2038-2046.	3.6	343
361	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
362	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	5.8	412
363	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	1.6	46

#	Article	IF	Citations
364	Emerging role of immunotherapy in urothelial carcinomaâ€"Immunobiology/biomarkers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 556-565.	0.8	23
365	Making urothelial carcinomas less immune to immunotherapy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 534-537.	0.8	2
366	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
368	Emerging role of checkpoint inhibition in localized bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 548-555.	0.8	19
370	Interdependent IL-7 and IFN-Î³ signalling in T-cell controls tumour eradication by combined Î±-CTLA-4+Î±-PD-1 therapy. Nature Communications, 2016, 7, 12335.	5.8	93
371	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	4.8	44
372	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nature Communications, 2016, 7, 13354.	5.8	224
373	Alteration of early dendritic cell activation by cancer cell lines predisposes immunosuppression, which cannot be reversed by TLR4 stimulation. Acta Biochimica Et Biophysica Sinica, 2016, 48, 1101-1111.	0.9	2
374	Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). Current Oncology Reports, 2016, 18, 72.	1.8	6
375	Imaging Biomarkers in Immunotherapy. Biomarkers in Cancer, 2016, 8s2, BIC.S31805.	3.6	31
376	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
377	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. Journal of Hematology and Oncology, 2016, 9, 116.	6.9	201
378	Itâ€™s TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6
379	Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open, 2016, 2, e000321.	1.8	37
380	Role of surgical consolidation in metastatic urothelial carcinoma. Current Opinion in Urology, 2016, 26, 573-580.	0.9	12
381	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 535-542.	0.9	9
382	Innovation in Bladder Cancer Immunotherapy. Journal of Immunotherapy, 2016, 39, 291-297.	1.2	4
383	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 556-563.	0.9	5

#	Article	IF	Citations
384	Drug Monographs: Atezolizumab and Everolimus. Hospital Pharmacy, 2016, 51, 810-814.	0.4	3
385	Immune checkpoint inhibitorâ€related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology, 2016, 85, 331-339.	1.2	177
386	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. International Immunopharmacology, 2016, 38, 81-89.	1.7	44
387	Phase I study with ONCOS-102 for the treatment of solid tumors â€“ an evaluation of clinical response and exploratory analyses of immune markers. , 2016, 4, 17.		155
388	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research, 2016, 4, 669-678.	1.6	117
389	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. Future Oncology, 2016, 12, 2049-2058.	1.1	8
390	Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 775-780.	0.6	9
391	Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma. Clinical Cancer Research, 2016, 22, 3025-3036.	3.2	124
392	Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers. Current Treatment Options in Oncology, 2016, 17, 40.	1.3	34
393	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 469-476.	0.8	8
394	Safety and Efficacy of Durvalumab (MEDI4736), an Antiâ€“Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3119-3125.	0.8	755
396	Mouse Models of Tumor Immunotherapy. Advances in Immunology, 2016, 130, 1-24.	1.1	30
397	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute, 2016, 108, djw144.	3.0	271
398	Bladder cancer. Lancet, The, 2016, 388, 2796-2810.	6.3	1,031
399	PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. OncoImmunology, 2016, 5, e1176653.	2.1	59
400	PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Human Pathology, 2016, 55, 182-189.	1.1	58
401	The PD-1:PD-L1 immune inhibitory checkpoint in Helicobacter pylori infection and gastric cancer: a comprehensive review and future perspectives. Porto Biomedical Journal, 2016, 1, 4-11.	0.4	22
402	Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. European Urology Focus, 2016, 2, 445-452.	1.6	63

#	Article	IF	Citations
404	Re: Genomic Classifier Identifies Men with Adverse Pathology After Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy. European Urology, 2016, 69, 539-540.	0.9	1
405	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
406	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€“Weighted Analysis From the National Cancer Data Base. Journal of Clinical Oncology, 2016, 34, 3529-3536.	0.8	70
407	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of Clinical Oncology, 2016, 34, 2627-2635.	0.8	69
408	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
409	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2016, 18, 21.	2.2	66
410	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. Journal of Clinical Oncology, 2016, 34, 3733-3739.	0.8	586
411	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
412	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer, 2016, 54, 139-148.	1.3	1,687
413	Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 191-203.	0.6	52
414	Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?. Clinical Genitourinary Cancer, 2016, 14, 183-187.	0.9	42
415	PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research, 2016, 4, 194-203.	1.6	321
416	Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. Journal of Clinical Oncology, 2016, 34, 780-785.	0.8	8
417	The safety and efficacy of gemcitabine for the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2016, 16, 255-271.	1.1	27
418	Pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2016, 16, 397-406.	1.4	56
419	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. Clinical Cancer Research, 2016, 22, 3057-3066.	3.2	217
420	Cancer immune contexture and immunotherapy. Current Opinion in Immunology, 2016, 39, 7-13.	2.4	132
421	Pharmacogenomics. Urologic Clinics of North America, 2016, 43, 77-86.	0.8	9

#	Article	IF	Citations
422	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 57-75.	1.5	46
423	Novel therapeutic targets in advanced urothelial carcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 106-115.	2.0	45
424	Radiologic Heterogeneity in Responses to Antiâ€“PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 12-17.	1.6	49
425	Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Annals of Oncology, 2016, 27, 294-299.	0.6	48
426	Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. European Journal of Surgical Oncology, 2016, 42, 735-743.	0.5	49
427	The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organsâ€”Part B: Prostate and Bladder Tumours. European Urology, 2016, 70, 106-119.	0.9	1,323
428	CTLA-4 and PD-1 Pathways. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 98-106.	0.6	1,644
429	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Clinical Oncology, 2016, 34, 1945-1952.	0.8	202
430	Improving Systemic Chemotherapy for Bladder Cancer. Current Oncology Reports, 2016, 18, 27.	1.8	42
431	B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumor Biology, 2016, 37, 9465-9472.	0.8	29
432	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. Journal of Clinical Oncology, 2016, 34, 2206-2211.	0.8	692
433	2015 and human cancer: back to overall survival. Future Oncology, 2016, 12, 1751-1754.	1.1	0
434	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. OncoImmunology, 2016, 5, e1091146.	2.1	66
435	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	1.1	160
436	Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy, 2016, 8, 351-365.	1.0	21
437	The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target. Future Oncology, 2016, 12, 595-600.	1.1	9
438	Novel therapies for advanced squamous cell carcinoma of the lung. Future Oncology, 2016, 12, 659-667.	1.1	11
439	Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 2016, 29, 347-358.	2.9	43

#	Article	IF	Citations
440	Re: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. European Urology, 2016, 69, 538-539.	0.9	3
441	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	1.7	34
442	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 175-181.	1.6	30
443	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications, 2016, 7, 10501.	5.8	1,163
444	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2016, 34, 987-1011.	0.8	141
445	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treatment Reviews, 2016, 45, 7-18.	3.4	354
446	Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. OncoImmunology, 2016, 5, e1145333.	2.1	12
447	Origins of Bladder Cancer. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 149-174.	9.6	140
448	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. Clinical Cancer Research, 2016, 22, 2261-2270.	3.2	217
449	Perioperative treatment and radical cystectomy for bladder cancer â€“ a population based trend analysis of 10,338 patients in the Netherlands. European Journal of Cancer, 2016, 54, 18-26.	1.3	44
450	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 4.e11-4.e17.	0.8	14
451	A Review of Neoadjuvant and Adjuvant Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer. Urology Practice, 2016, 3, 41-49.	0.2	0
452	Expanding the antimalarial toolkit: Targeting hostâ€“parasite interactions. Journal of Experimental Medicine, 2016, 213, 143-153.	4.2	22
453	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 789-800.	0.5	401
454	The management of immune-related adverse events associated with immune checkpoint blockade. Expert Review of Quality of Life in Cancer Care, 2016, 1, 89-97.	0.6	15
455	Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clinical Cancer Research, 2016, 22, 3849-3859.	3.2	109
456	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. International Journal of Clinical Oncology, 2016, 21, 462-473.	1.0	255
457	Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, S9-S14.	2.0	0

#	Article	IF	Citations
458	Coinhibitory Pathways in Immunotherapy for Cancer. Annual Review of Immunology, 2016, 34, 539-573.	9.5	718
459	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13, 273-290.	12.5	909
460	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs, 2016, 8, 593-603.	2.6	156
461	Immune checkpoint pathways: perspectives on myeloid malignancies. Leukemia and Lymphoma, 2016, 57, 995-1001.	0.6	4
462	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. Current Oncology Reports, 2016, 18, 21.	1.8	39
463	Targeting Oral Cancer. , 2016, , .		0
464	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. Journal of Clinical Oncology, 2016, 34, 1500-1509.	0.8	72
465	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. European Urology Focus, 2016, 1, 265-268.	1.6	45
466	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, The, 2016, 387, 1909-1920.	6.3	3,077
467	Role for anti-PD-L1 immune checkpoint inhibitor in advanced urothelial carcinoma. Lancet, The, 2016, 387, 1881-1882.	6.3	8
468	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity, 2016, 44, 609-621.	6.6	566
469	Immunotherapy in Head and Neck Cancers. , 2016, , 211-224.		0
471	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. Critical Reviews in Oncology/Hematology, 2016, 98, 122-136.	2.0	24
472	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, The, 2016, 387, 1837-1846.	6.3	2,390
473	Development of immuno-oncology drugs â€" from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
474	Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research, 2016, 22, 2102-2104.	3.2	31
475	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. Investigational New Drugs, 2016, 34, 236-242.	1.2	21
476	Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology, 2016, 27, 998-1005.	0.6	72

#	Article	IF	Citations
477	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	1.4	40
478	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clinical Cancer Research, 2016, 22, 793-801.	3.2	60
479	Atezolizumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. Journal of Clinical Oncology, 2016, 34, 833-842.	0.8	517
480	Efficacy of PD-1 blockade in tumors with MMR deficiency. Immunotherapy, 2016, 8, 1-3.	1.0	53
481	moCluster: Identifying Joint Patterns Across Multiple Omics Data Sets. Journal of Proteome Research, 2016, 15, 755-765.	1.8	88
482	Cancer immunotherapy targeting neoantigens. Seminars in Immunology, 2016, 28, 22-27.	2.7	199
483	Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 2016, 22, 26-36.	15.2	296
484	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. OncoImmunology, 2016, 5, e1062969.	2.1	27
485	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Annals of Oncology, 2016, 27, 49-61.	0.6	108
486	Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22.	2.4	55
487	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. European Urology, 2016, 69, 634-641.	0.9	53
488	Reprogramming away from the exhausted T cell state. Seminars in Immunology, 2016, 28, 35-44.	2.7	25
489	Emerging Bladder Cancer Biomarkers and Targets of Therapy. Urologic Clinics of North America, 2016, 43, 63-76.	0.8	21
490	An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clinical Cancer Research, 2016, 22, 54-60.	3.2	44
491	Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatric Research, 2016, 79, 371-377.	1.1	12
492	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clinical Cancer Research, 2016, 22, 1969-1977.	3.2	170
493	Immunotherapy for Resected Pulmonary Metastases. Thoracic Surgery Clinics, 2016, 26, 69-78.	0.4	3
494	A step closer to individualized treatment for bladder cancer. Nature Reviews Urology, 2016, 13, 127-128.	1.9	2

#	Article	IF	Citations
495	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Annals of Oncology, 2016, 27, 214-224.	0.6	86
496	The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmetteâ€“GuÃ©rin failures for non-muscle-invasive bladder cancer. Therapeutic Advances in Urology, 2016, 8, 29-37.	0.9	5
497	A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 76-81.	0.9	12
498	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyondâ€”A Comprehensive Review of the Current Literature. Journal of Urology, 2016, 195, 254-263.	0.2	99
499	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancerâ€”Does pT0 Predict Better Survival than pTa/Tis/T1?. Journal of Urology, 2016, 195, 886-893.	0.2	71
500	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2016, 69, 624-633.	0.9	25
501	Immune checkpoint inhibitors: a new frontier in bladder cancer. World Journal of Urology, 2016, 34, 49-55.	1.2	15
502	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. Journal of Urology, 2016, 195, 277-282.	0.2	54
503	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. Biology of Blood and Marrow Transplantation, 2016, 22, 17-22.	2.0	16
505	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer â€” At What Cost? Eur Urol 2016;69:642â€“44. European Urology, 2016, 69, 644-645.	0.9	0
506	More than a scaffold: Stromal modulation of tumor immunity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 3-13.	3.3	32
507	Predicting Response to Intravesical Bacillus Calmette-GuÃ©rin Immunotherapy: Are We Moving Forward?. European Urology, 2016, 69, 201-202.	0.9	8
508	The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World Journal of Urology, 2016, 34, 181-187.	1.2	73
509	Biomarkers for immunotherapy in genitourinary malignancies. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 205-213.	0.8	14
510	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2017, 15, 77-85.	0.9	40
511	Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, 145-151.e2.	0.9	40
512	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. European Journal of Molecular and Clinical Medicine, 2017, 3, 9.	0.5	18
513	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95

#	Article	IF	Citations
514	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. Breast Cancer, 2017, 24, 111-120.	1.3	21
515	Elements of cancer immunity and the cancerâ€“immune set point. Nature, 2017, 541, 321-330.	13.7	3,558
516	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1117-1122.	3.3	378
517	Comprehensive screening for PD-L1 expression in thyroid cancer. Endocrine-Related Cancer, 2017, 24, 97-106.	1.6	119
518	Cancer immunotherapy â€" immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology, 2017, 13, 195-207.	4.3	515
519	A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 39.e1-39.e7.	0.8	34
520	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Modern Pathology, 2017, 30, 577-586.	2.9	132
521	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. Cancer Treatment Reviews, 2017, 53, 138-145.	3.4	20
522	Strategies to design clinical studies to identify predictive biomarkers in cancer research. Cancer Treatment Reviews, 2017, 53, 79-97.	3.4	80
523	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	5.1	307
524	Checkpoint inhibition: new treatment options in urologic cancer. Acta Clinica Belgica, 2017, 72, 24-28.	0.5	13
525	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44
526	Novel immune check point inhibiting antibodies in cancer therapyâ€"Opportunities and challenges. Drug Resistance Updates, 2017, 30, 39-47.	6.5	98
527	Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. Cancer Treatment Reviews, 2017, 54, 1-9.	3.4	44
528	Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 335-341.	0.8	66
529	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2017, 77, 1035-1046.	0.4	15
530	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	12.5	760
531	Redirecting the focus of cancer immunotherapy to premalignant conditions. Cancer Letters, 2017, 391, 83-88.	3.2	24

#	Article	IF	Citations
532	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. European Journal of Cancer, 2017, 75, 24-32.	1.3	162
533	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nature Reviews Urology, 2017, 14, 244-255.	1.9	108
534	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nature Communications, 2017, 8, 14572.	5.8	279
535	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. Cells Tissues Organs, 2017, 203, 128-138.	1.3	20
536	A review of the importance of immune responses in luminal B breast cancer. OncoImmunology, 2017, 6, e1282590.	2.1	5
537	ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of Hepatology, 2017, 66, 942-951.	1.8	53
538	Patient-derived xenografts as in vivo models for research in urological malignancies. Nature Reviews Urology, 2017, 14, 267-283.	1.9	65
539	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, R123-R144.	1.6	64
541	PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology, Immunotherapy, 2017, 66, 551-564.	2.0	253
542	T cell costimulatory receptor CD28 is a primary target for PD-1â€“mediated inhibition. Science, 2017, 355, 1428-1433.	6.0	1,229
543	Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 457.e15-457.e21.	0.8	18
544	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Journal of Translational Medicine, 2017, 15, 46.	1.8	85
545	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology, 2017, 92, 283-290.	0.9	36
546	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. OncoImmunology, 2017, 6, e1278100.	2.1	65
547	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	5.8	689
548	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research, 2017, 5, 312-318.	1.6	354
549	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. Molecular Diagnosis and Therapy, 2017, 21, 337-343.	1.6	4
550	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. Journal of Clinical Pathology, 2017, 70, 255-259.	1.0	97

#	Article	IF	Citations
551	PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. , 2017, , 115-146.		0
552	LAG-3 Protein Expression in Nonâ€“Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192
553	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	1.9	89
554	Proteogenomic analysis of NCC-S1M, a gastric cancer stem cell-like cell line that responds to anti-PD-1. Biochemical and Biophysical Research Communications, 2017, 484, 631-635.	1.0	5
555	Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. International Journal of Infectious Diseases, 2017, 56, 221-228.	1.5	112
556	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treatment Reviews, 2017, 54, 58-67.	3.4	324
557	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. JAMA Dermatology, 2017, 153, 285.	2.0	39
558	<scp>TAM</scp> receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunological Reviews, 2017, 276, 165-177.	2.8	125
559	HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. OncoImmunology, 2017, 6, e1293214.	2.1	23
560	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
561	Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2017, 15, e697-e706.	0.9	17
562	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nature Immunology, 2017, 18, 255-262.	7.0	361
563	Immunotherapy: a new treatment paradigm in bladder cancer. Current Opinion in Oncology, 2017, 29, 184-195.	1.1	40
564	Papilloma-pseudovirus eradicates intestinal tumours and triples the lifespan of ApcMin/+ mice. Nature Communications, 2017, 8, 15004.	5.8	8
566	<scp>PD</scp>â€Ł1 expression in extrahepatic cholangiocarcinoma. Histopathology, 2017, 71, 383-392.	1.6	62
567	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. Archives of Pathology and Laboratory Medicine, 2017, 141, 851-861.	1.2	82
568	Childhood Acute Lymphoblastic Leukemia. , 2017, , .		2
569	Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 271-280.	1.4	15

#	Article	IF	Citations
570	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. Journal of Controlled Release, 2017, 256, 26-45.	4.8	41
571	FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist, 2017, 22, 743-749.	1.9	116
572	Novel immune checkpoint blocker to treat Merkel cell carcinoma. OncoImmunology, 2017, 6, e1315496.	2.1	1
573	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology, 2017, 72, 477-481.	0.9	36
574	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.0	8
575	Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy. Medical Oncology, 2017, 34, 117.	1.2	7
576	Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs, 2017, 77, 1077-1089.	4.9	67
577	MP34-04 POST-CHEMOTHERAPY PD-L1 EXPRESSION CORRELATES WITH CLINICAL OUTCOMES IN JAPANESE BLADDER CANCER PATIENTS TREATED WITH TOTAL CYSTECTOMY.. Journal of Urology, 2017, 197, .	0.2	0
578	Integrative Analysis Identifies a Novel AXLâ€“PI3 Kinaseâ€“PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722.	3.2	91
579	Age-Related Changes in Plasma Extracellular Vesicle Characteristics and Internalization by Leukocytes. Scientific Reports, 2017, 7, 1342.	1.6	193
580	Checkpoint inhibitors in hematological malignancies. Journal of Hematology and Oncology, 2017, 10, 103.	6.9	106
581	Patterns of PDâ€1, PDâ€L1, and PDâ€L2 expression in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26613.	0.8	43
582	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. Cancer Immunology, Immunotherapy, 2017, 66, 1113-1121.	2.0	29
583	Immunotherapy in genitourinary malignancies. Journal of Hematology and Oncology, 2017, 10, 95.	6.9	32
584	A systematic review and network metaâ€analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Medicine, 2017, 6, 1143-1153.	1.3	60
586	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer, 2017, 123, 3285-3290.	2.0	170
587	PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. American Journal of Surgical Pathology, 2017, 41, 326-333.	2.1	113
588	Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer. Pathology Research and Practice, 2017, 213, 766-772.	1.0	17

#	Article	IF	Citations
589	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. Cancer Journal (Sudbury, Mass), 2017, 23, 138-143.	1.0	30
590	Biomarkers for precision medicine in bladder cancer. International Journal of Clinical Oncology, 2017, 22, 207-213.	1.0	30
591	Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clinical and Experimental Nephrology, 2017, 21, 732-740.	0.7	14
592	Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discovery, 2017, 7, 188-201.	7.7	997
593	Advances in urology 2015â€“2016. Journal of Clinical Urology, 2017, 10, 39-48.	0.1	0
594	Atezolizumab: A PD-L1â€“Blocking Antibody for Bladder Cancer. Clinical Cancer Research, 2017, 23, 1886-1890.	3.2	189
595	Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PDâ€1 antibodies. International Journal of Cancer, 2017, 140, 1609-1619.	2.3	16
596	On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nature Reviews Urology, 2017, 14, 98-106.	1.9	30
597	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research, 2017, 23, 3158-3167.	3.2	426
599	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 2017, 153, 812-826.	0.6	650
600	Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. Cancer Biotherapy and Radiopharmaceuticals, 2017, 32, 149-160.	0.7	93
601	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist, 2017, 22, 963-971.	1.9	145
602	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 480-492.	1.6	284
603	Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 209-219.	1.4	7
604	Engineering challenges for brain tumor immunotherapy. Advanced Drug Delivery Reviews, 2017, 114, 19-32.	6.6	62
605	Immunotherapy: The Wave of the Future in Bladder Cancer?. Clinical Genitourinary Cancer, 2017, 15, S3-S17.	0.9	8
606	Recent progress in immunotherapy for urological cancer. International Journal of Urology, 2017, 24, 735-742.	0.5	12
607	Evolving adoptive cellular therapies in urological malignancies. Lancet Oncology, The, 2017, 18, e341-e353.	5.1	22

#	Article	IF	Citations
608	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treatment Reviews, 2017, 58, 22-33.	3.4	76
609	Optimizing management of upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 492-498.	0.8	18
611	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology, 2017, 6, e1312240.	2.1	68
612	In Vivo Imaging of the Programmed Death Ligand 1 by ¹⁸F PET. Journal of Nuclear Medicine, 2017, 58, 1852-1857.	2.8	84
613	PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness. Scientific Reports, 2017, 7, 2074.	1.6	21
614	Biallelic PMS2 Mutation and Heterozygous DICER1 Mutation Presenting as Constitutional Mismatch Repair Deficiency With Corpus Callosum Agenesis: Case Report and Review of Literature. Journal of Pediatric Hematology/Oncology, 2017, 39, e381-e387.	0.3	3
615	Assessment of programmed deathâ€ligand 1 expression and tumorâ€associated immune cells in pediatric cancer tissues. Cancer, 2017, 123, 3807-3815.	2.0	135
616	Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Annals of Oncology, 2017, 28, 1988-1995.	0.6	326
617	Tackling non-muscle invasive bladder cancer in the clinic. Expert Review of Anticancer Therapy, 2017, 17, 467-480.	1.1	11
618	Treatment with anti-programmed cell death 1 (PD-1) antibody restored postoperative CD8+ T cell dysfunction by surgical stress. Biomedicine and Pharmacotherapy, 2017, 89, 1235-1241.	2.5	15
619	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2017, 147, 500-506.	0.4	52
620	Immunomodulation for glioblastoma. Current Opinion in Neurology, 2017, 30, 361-369.	1.8	21
621	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. Acta Neuropathologica, 2017, 134, 297-316.	3.9	23
622	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
623	Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2017, 18, 672-681a.	5.1	49
624	CD8 Tâ€cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology, 2017, 151, 146-153.	2.0	12
625	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
626	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology, 2017, 28, 1036-1041.	0.6	207

#	Article	IF	Citations
627	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	3.5	55
628	Cancer Immunotherapy: Whence and Whither. Molecular Cancer Research, 2017, 15, 635-650.	1.5	30
629	Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy. Cellular Physiology and Biochemistry, 2017, 41, 907-920.	1.1	88
630	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell, 2017, 31, 476-485.	7.7	116
631	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. Signal Transduction and Targeted Therapy, 2017, 2, .	7.1	35
632	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. Immunotherapy, 2017, 9, 451-460.	1.0	12
635	Contemporary update on neoadjuvant therapy for bladder cancer. Nature Reviews Urology, 2017, 14, 348-358.	1.9	24
636	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
637	Correlation between messenger RNA expression and protein expression of immune checkpointâ€“associated molecules in bladder urothelial carcinoma: A retrospective study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 257-263.	0.8	29
638	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. Expert Opinion on Biological Therapy, 2017, 17, 735-746.	1.4	66
639	Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. Oral Oncology, 2017, 68, 36-43.	0.8	71
640	Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Investigational New Drugs, 2017, 35, 529-536.	1.2	128
641	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, The, 2017, 389, 67-76.	6.3	1,728
642	A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Annals of Oncology, 2017, 28, 798-803.	0.6	43
643	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy, 2017, 9, 5-8.	1.0	20
644	Immuno-Oncology: The Third Paradigm in Early Drug Development. Targeted Oncology, 2017, 12, 125-138.	1.7	22
645	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer, 2017, 103, 44-51.	0.9	91
646	Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer. British Journal of Radiology, 2017, 90, 20160500.	1.0	17

#	Article	IF	Citations
647	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2â€“Positive Metastatic Bladder Cancer. Journal of Clinical Oncology, 2017, 35, 48-55.	0.8	165
648	Nonâ€“muscleâ€invasive bladder cancer: Intravesical treatments beyond Bacille ‹scp›C‹/scp›almetteâ€‹‹scp›G‹/scp›uÃ©rin. Cancer, 2017, 123, 390-400.	2.0	37
650	Molecular Pathways: The Necrosomeâ€”A Target for Cancer Therapy. Clinical Cancer Research, 2017, 23, 1132-1136.	3.2	35
651	Ex Vivo Engineering of the Tumor Microenvironment. Cancer Drug Discovery and Development, 2017, , .	0.2	4
652	Microfluidics and Future of Cancer Diagnostics. Cancer Drug Discovery and Development, 2017, , 55-70.	0.2	1
653	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology, 2017, 71, 281-289.	0.9	56
654	Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.		14
655	Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 225-232.	1.5	20
656	Immunological profiling of molecularly classified high-risk endometrial cancers identifies ‹i›POLE‹/i›-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology, 2017, 6, e1264565.	2.1	102
657	Bladder cancer cells induce immunosuppression of T cells by supporting PDâ€L1 expression in tumour macrophages partially through interleukin 10. Cell Biology International, 2017, 41, 177-186.	1.4	40
658	Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma. Clinical Pharmacology and Therapeutics, 2017, 102, 305-312.	2.3	110
659	Localized Multiâ€Component Delivery Platform Generates Local and Systemic Antiâ€Tumor Immunity. Advanced Functional Materials, 2017, 27, 1604366.	7.8	40
660	Rheumatic and Musculoskeletal Immuneâ€Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care and Research, 2017, 69, 1751-1763.	1.5	292
661	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research, 2017, 5, 17-28.	1.6	130
662	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, The, 2017, 389, 255-265.	6.3	3,872
663	Innate immune signaling and regulation in cancer immunotherapy. Cell Research, 2017, 27, 96-108.	5.7	291
664	Update of systemic immunotherapy for advanced urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 678-686.	0.8	12
665	Prospects for precision therapy of bladder urothelial carcinoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 261-274.	0.4	1

#	Article	IF	Citations
666	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. Seminars in Immunology, 2017, 34, 114-122.	2.7	29
667	Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. ESMO Open, 2017, 2, e000236.	2.0	30
668	Immuno-oncology in urothelial carcinoma: who or what will ultimately sit on the iron throne?. Immunotherapy, 2017, 9, 951-954.	1.0	5
669	Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-⁶⁴Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. Molecular Pharmaceutics, 2017, 14, 3978-3986.	2.3	66
670	Atezolizumab in invasive and metastatic urothelial carcinoma. Expert Review of Clinical Pharmacology, 2017, 10, 1295-1301.	1.3	20
671	Personalized peptide vaccination as secondâ€line treatment for metastatic upper tract urothelial carcinoma. Cancer Science, 2017, 108, 2430-2437.	1.7	14
673	Endocrine side effects of cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, T331-T347.	1.6	131
674	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. Cellular Immunology, 2017, 322, 1-14.	1.4	114
675	Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. Journal of Immunotherapy, 2017, 40, 323-333.	1.2	68
676	Tumor cell-associated immune checkpoint molecules â€“ Drivers of malignancy and stemness. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 571-583.	3.3	54
677	The evolutionary nature of the cancer immunotherapy revolution. Future Oncology, 2017, 13, 1565-1567.	1.1	4
678	Mechanisms regulating T-cell infiltration and activity in solid tumors. Annals of Oncology, 2017, 28, xii18-xii32.	0.6	276
679	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. American Journal of Clinical Pathology, 2017, 148, 441-449.	0.4	19
680	ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 2017, 28, 2340-2366.	0.6	451
681	MicroRNA-155 induction via TNF-Î± and IFN-Î³ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. Journal of Biological Chemistry, 2017, 292, 20683-20693.	1.6	105
682	Checkpoint immunotherapy in head and neck cancers. Cancer and Metastasis Reviews, 2017, 36, 475-489.	2.7	33
683	The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. Melanoma Research, 2017, 27, 519-523.	0.6	16
685	Erythema nodosumâ€like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapyâ€”Report of 2 patients. Journal of Cutaneous Pathology, 2017, 44, 1080-1086.	0.7	48

#	Article	IF	Citations
686	Relationship of tumor <scp>PD</scp>â€L1 (<scp>CD</scp>274) expression with lower mortality in lung highâ€grade neuroendocrine tumor. Cancer Medicine, 2017, 6, 2347-2356.	1.3	39
688	Expression of PD-L1 in Hormone-naÃ¯ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	3.2	77
689	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. Biochemistry, 2017, 56, 5428-5439.	1.2	23
690	PD-L1 is an activation-independent marker of brown adipocytes. Nature Communications, 2017, 8, 647.	5.8	97
691	CXCR4 Ligands: The Next Big Hit?. Journal of Nuclear Medicine, 2017, 58, 77S-82S.	2.8	118
693	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2017, 38, 1512-1520.	2.8	56
694	Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. Molecular Imaging, 2017, 16, 153601211771845.	0.7	47
696	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemotherapy and Pharmacology, 2017, 80, 591-598.	1.1	47
697	Tumor vesical: presente y futuro. Medicina ClÃ¬nica, 2017, 149, 449-455.	0.3	101
698	Nivolumab for the treatment of bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1309-1315.	1.4	13
700	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. Modern Pathology, 2017, 30, 1622-1632.	2.9	62
701	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Scientific Reports, 2017, 7, 5532.	1.6	166
703	Challenges in the design of reliable immuno-oncology mouse models to inform drug development. Future Medicinal Chemistry, 2017, 9, 1313-1317.	1.1	4
704	Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer. ACS Nano, 2017, 11, 8690-8706.	7.3	108
705	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325.	3.3	46
706	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110.	13.7	501
707	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. JAMA Oncology, 2017, 3, e172411.	3.4	750
708	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, 2017, 19, 64.	1.8	106

#	Article	IF	Citations
710	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology, 2017, 6, e1346764.	2.1	69
711	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Annals of Oncology, 2017, 28, 2377-2385.	0.6	631
712	Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials, 2017, 14, 611-620.	0.7	7
713	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. Expert Opinion on Emerging Drugs, 2017, 22, 347-355.	1.0	0
714	Multiplex three-dimensional optical mapping of tumor immune microenvironment. Scientific Reports, 2017, 7, 17031.	1.6	41
716	ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 120, 120-126.	2.0	19
717	Bladder cancer: Present and future. Medicina ClÃ¬nica (English Edition), 2017, 149, 449-455.	0.1	51
718	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186
719	Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Science Translational Medicine, 2017, 9, .	5.8	131
720	Systematic Review of Immune Checkpoint Inhibition in Urological Cancers. European Urology, 2017, 72, 411-423.	0.9	89
721	Posttranscriptional Control of PD-L1 Expression by 17Î²-Estradiol via PI3K/Akt Signaling Pathway in ERÎ±-Positive Cancer Cell Lines. International Journal of Gynecological Cancer, 2017, 27, 196-205.	1.2	68
723	Targeted therapies for renal cell carcinoma. Nature Reviews Nephrology, 2017, 13, 496-511.	4.1	185
724	Programmed Death Ligand 1 Expression in Paired Nonâ€“Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479.	1.1	35
725	Landmarks in the treatment of muscle-invasive bladder cancer. Nature Reviews Urology, 2017, 14, 565-574.	1.9	122
726	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metabolism, 2017, 26, 94-109.	7.2	374
727	A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine, 2017, 15, 150.	1.8	26
728	Checkpoint inhibition for advanced mucosal melanoma. European Journal of Dermatology, 2017, 27, 160-165.	0.3	17
729	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. Journal of Physical Education and Sports Management, 2017, 3, a001974.	0.5	54

#	Article	IF	Citations
730	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 1MPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 14-20.	0.8	67
731	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Diseases, 2017, 20, 28-35.	2.0	120
732	Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 2017, 24, 134-140.	2.2	72
733	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annual Review of Cancer Biology, 2017, 1, 241-255.	2.3	25
734	Epidemiology of Bladder Cancer. , 2017, , 511-522.		3
735	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. BJU International, 2017, 119, 579-584.	1.3	16
736	Basis for molecular diagnostics and immunotherapy for esophageal cancer. Expert Review of Anticancer Therapy, 2017, 17, 33-45.	1.1	23
737	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. Journal of Cutaneous Pathology, 2017, 44, 158-176.	0.7	186
738	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Annals of Oncology, 2017, 28, 57-74.	0.6	45
739	Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer. Bioengineered, 2017, 8, 367-373.	1.4	7
740	Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Therapy, 2017, 24, 21-30.	2.3	61
741	Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer. European Urology, 2017, 71, 854-857.	0.9	22
742	Immunotherapy of melanoma. European Journal of Surgical Oncology, 2017, 43, 594-603.	0.5	21
743	Immunotherapy for the Treatment of Urothelial Carcinoma. Journal of Urology, 2017, 197, 14-22.	0.2	87
744	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465.	3.2	126
745	Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Research, 2017, 27, 151-153.	5.7	116
746	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. European Urology, 2017, 71, 237-246.	0.9	62
747	Port-Site Metastases After Robotic Radical Cystectomy: A Systematic Review and Management Options. Clinical Genitourinary Cancer, 2017, 15, 440-444.	0.9	15

#	Article	IF	Citations
748	Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. Cancer Immunology, Immunotherapy, 2017, 66, 281-298.	2.0	54
749	Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 38.e1-38.e8.	0.8	19
750	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffeyâ€“Holden Prostate Cancer Academy Meeting. Prostate, 2017, 77, 123-144.	1.2	6
751	Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. Journal of Urology, 2017, 197, 690-697.	0.2	81
752	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nature Reviews Urology, 2017, 14, 15-25.	1.9	210
753	Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine, 2017, 35, 1094-1100.	1.7	63
754	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer, 2017, 15, 23-30.e2.	0.9	50
755	A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer. Cancer Immunology, Immunotherapy, 2017, 66, 309-318.	2.0	45
756	Local checkpoint inhibition of CTLAâ€4 as a monotherapy or in combination with antiâ€PD1 prevents the growth of murine bladder cancer. European Journal of Immunology, 2017, 47, 385-393.	1.6	64
757	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth and Metastasis, 2017, 10, 117906441770928.	3.5	24
758	CDK4/6 Inhibitors in Cancer Therapy: AÂNovel Treatement Strategy for Bladder Cancer. Bladder Cancer, 2017, 3, 79-88.	0.2	21
759	Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Japanese Journal of Clinical Immunology, 2017, 40, 54-59.	0.0	12
760	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Japanese Journal of Clinical Immunology, 2017, 40, 68-77.	0.0	22
761	Multiple Myeloma and the immune microenvironment. Current Cancer Drug Targets, 2017, 17, 1-1.	0.8	59
762	Cancer vaccines at the age of immune checkpoint inhibitors: reasonable approach as combination therapy in advanced urothelial carcinoma?. Annals of Oncology, 2017, 28, 680-682.	0.6	4
763	Tumor Lysis Syndrome Following a Single Atezolizumab Infusion for Metastatic Urothelial Carcinoma Involving Both Upper and Lower Tract. Archives in Cancer Research, 2017, 05, .	0.3	2
764	Targeting immune checkpoints in malignant glioma. Oncotarget, 2017, 8, 7157-7174.	0.8	42
765	Chemotherapy and Targeted Agents. , 2017, , 339-354.		3

#	Article	IF	Citations
766	New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy, 2017, Volume 8, 67-78.	1.3	27
767	Taking it to the HILT: High-intensity local treatment with radical cystectomy for metastatic bladder cancer. Canadian Urological Association Journal, 2017, 11, 249-50.	0.3	0
768	New Immunotherapy Strategies in Breast Cancer. International Journal of Environmental Research and Public Health, 2017, 14, 68.	1.2	76
769	Microparticles and Nanoparticles for Cancer-Targeting Vaccines. , 2017, , 171-183.		2
770	Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers, 2017, 9, 15.	1.7	30
771	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. Theranostics, 2017, 7, 3585-3594.	4.6	214
772	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	2.2	61
773	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. Frontiers in Immunology, 2017, 8, 1617.	2.2	43
774	A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. Journal of Immunology Research, 2017, 2017, 1-9.	0.9	34
775	Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs. International Journal of Genomics, 2017, 2017, 1-9.	0.8	40
776	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. BioMed Research International, 2017, 2017, 1-7.	0.9	65
777	Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report. Neurologia Medico-Chirurgica, 2017, 57, 191-197.	1.0	18
778	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. Translational Andrology and Urology, 2017, 6, 1067-1080.	0.6	19
779	Cost of illness of urothelial bladder cancer in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 433-442.	0.7	15
780	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 1487-1502.	1.0	12
781	Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas. Oncotarget, 2017, 8, 104946-104959.	0.8	7
782	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Medicine, 2017, 14, e1002309.	3.9	256
783	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. BMC Cancer, 2017, 17, 618.	1.1	42

#	Article	IF	Citations
784	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. BMC Cancer, 2017, 17, 690.	1.1	41
785	Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016. , 2017, 5, 55.		5
786	Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. , 2017, 5, 81.		33
787	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
788	High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 2017, 8, 18021-18030.	0.8	46
789	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. Emerging Topics in Life Sciences, 2017, 1, 471-486.	1.1	5
790	The landscape of genetics and biomarkers in bladder cancer. Translational Andrology and Urology, 2017, 6, 1027-1030.	0.6	4
791	Cancer Immunotherapy. , 2017, , 32-65.		1
792	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
793	Use of Adjuvant Chemotherapy in Patients with Advanced Bladder Cancer after Neoadjuvant Chemotherapy. Bladder Cancer, 2017, 3, 181-189.	0.2	14
794	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Design, Development and Therapy, 2017, Volume 11, 2851-2860.	2.0	34
795	Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer. OncoTargets and Therapy, 2017, Volume 10, 2675-2683.	1.0	54
796	Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. Cancer Management and Research, 2018, Volume 10, 1-11.	0.9	23
797	Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. Journal of Cancer, 2017, 8, 332-344.	1.2	20
798	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget, 2017, 8, 90215-90224.	0.8	68
799	B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway. Journal of Cancer, 2017, 8, 816-824.	1.2	71
800	The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy. Molecular and Clinical Oncology, 2017, 7, 1112-1118.	0.4	6
801	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	0.5	49

#	Article	IF	Citations
802	The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung. Oncology Reports, 2017, 38, 2189-2196.	1.2	5
803	Circulating Tumor Cells (CTCs) as Biomarker for PD-1/PD-L1 Blockade Immunotherapy. Journal of Cancer Science & Therapy, 2017, 09, .	1.7	0
804	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. Emerging Topics in Life Sciences, 2017, 1, 447-456.	1.1	2
805	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget, 2017, 8, 91779-91794.	0.8	298
806	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Oncotarget, 2017, 8, 41932-41946.	0.8	95
807	PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget, 2017, 8, 24644-24651.	0.8	146
808	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. Journal of Clinical Oncology, 2017, 35, 1770-1777.	0.8	27
809	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	0.8	348
810	Immune Checkpoint Blockade in Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2017, 35, 2109-2112.	0.8	11
811	Evolving Treatment of Advanced Urothelial Cancer. Journal of Oncology Practice, 2017, 13, 309-315.	2.5	18
812	Avelumab, an Antiâ€“Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. Journal of Clinical Oncology, 2017, 35, 2117-2124.	0.8	538
813	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	1.8	11
814	Genetic and immune features of resectable malignant brainstem gliomas. Oncotarget, 2017, 8, 82571-82582.	0.8	12
815	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. JCO Precision Oncology, 2017, 1, 1-15.	1.5	57
816	Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers. Oncotarget, 2017, 8, 58887-58902.	0.8	22
817	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. Oncotarget, 2017, 8, 77415-77423.	0.8	68
818	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States. European Urology, 2018, 73, 800-806.	0.9	26
819	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) Tj ETQq1 1 0.784314 rgBT /Overl	2.8	96

#	Article	IF	Citations
820	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Current Oncology Reports, 2018, 20, 24.	1.8	35
821	An <scp>FGFR</scp> 3/ <scp>MYC</scp> positive feedback loop provides new opportunities for targeted therapies in bladder cancers. EMBO Molecular Medicine, 2018, 10, .	3.3	54
822	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. Methods in Molecular Biology, 2018, 1719, 209-221.	0.4	46
823	Systemic immune-inflammation index in germ-cell tumours. British Journal of Cancer, 2018, 118, 831-838.	2.9	70
824	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. Clinical Medicine Insights: Oncology, 2018, 12, 117955491875907.	0.6	4
825	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. Molecular Cancer Research, 2018, 16, 805-812.	1.5	169
826	Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 248-255.	3.3	20
827	Peptidomics. Methods in Molecular Biology, 2018, , .	0.4	5
828	Characterization of TIM-3 expression and its prognostic value in patients with surgically resected lung adenocarcinoma. Lung Cancer, 2018, 121, 18-24.	0.9	24
829	Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management, 2018, 7, BMT05.	0.2	4
830	PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients. Memo - Magazine of European Medical Oncology, 2018, 11, 43-46.	0.3	23
831	IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class Iâ€“Deficient Tumors. Cancer Immunology Research, 2018, 6, 685-695.	1.6	39
832	Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis. Cancer, 2018, 124, 2507-2514.	2.0	13
833	Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients. Hematological Oncology, 2018, 36, 591-599.	0.8	14
834	PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature. Annals of Diagnostic Pathology, 2018, 34, 135-141.	0.6	18
836	Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. Current Oncology Reports, 2018, 20, 48.	1.8	40
837	Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 287-295.	0.8	10
838	Role of PD-1 during effector CD8 T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4749-4754.	3.3	327

#	Article	IF	Citations
840	Present status and future perspective of peptideâ€based vaccine therapy for urological cancer. Cancer Science, 2018, 109, 550-559.	1.7	42
841	Role of immunotherapy in bacillus Calmetteâ€“GuÃ©rin-unresponsive nonâ€“muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 103-108.	0.8	20
842	TGFÎ² attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature, 2018, 554, 544-548.	13.7	3,359
843	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. Oncogenesis, 2018, 7, 2.	2.1	68
844	Intratumoral administration of IL2- and TNF-based fusion proteins cures cancer without establishing protective immunity. Immunotherapy, 2018, 10, 177-188.	1.0	13
845	A practical guide to bladder cancer pathology. Nature Reviews Urology, 2018, 15, 143-154.	1.9	36
846	Checkpoint molecule expression by B and T cell lymphomas in dogs. Veterinary and Comparative Oncology, 2018, 16, 352-360.	0.8	25
847	Stromal Contributions to Tumor Progression in Urothelial Carcinoma of the Bladder. Molecular Pathology Library, 2018, , 209-220.	0.1	0
848	Requisite for Collection and Distribution of Tissue and Fluid Specimens for Molecular Diagnostics and Discovery in Bladder Cancer. Molecular Pathology Library, 2018, , 103-116.	0.1	0
849	PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer. Cancer Biology and Therapy, 2018, 19, 373-380.	1.5	56
850	Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. Journal of the National Cancer Institute, 2018, 110, 448-459.	3.0	112
851	Optimizing Breast Cancer Management. Cancer Treatment and Research, 2018, , .	0.2	2
852	Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treatment Reviews, 2018, 64, 11-20.	3.4	76
853	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. JAMA Oncology, 2018, 4, 537.	3.4	104
854	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. American Journal of Clinical Pathology, 2018, 149, 253-261.	0.4	22
858	Immune Checkpoint Blockade for Breast Cancer. Cancer Treatment and Research, 2018, 173, 155-165.	0.2	69
859	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer Journal (Sudbury, Mass), 2018, 24, 47-53.	1.0	287
860	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. Journal of the National Cancer Institute, 2018, 110, 787-790.	3.0	123

#	Article	IF	Citations
861	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology, 2018, 73, 462-468.	0.9	36
862	Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression. Modern Pathology, 2018, 31, 623-632.	2.9	102
863	Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. British Journal of Dermatology, 2018, 178, 1199-1203.	1.4	25
865	Merkel cell carcinoma: An update and review. Journal of the American Academy of Dermatology, 2018, 78, 445-454.	0.6	90
866	COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Molecular Cancer Therapeutics, 2018, 17, 474-483.	1.9	32
867	miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer and Metastasis Reviews, 2018, 37, 33-44.	2.7	152
868	Pembrolizumab for the treatment of bladder cancer. Expert Review of Anticancer Therapy, 2018, 18, 107-114.	1.1	12
869	Cancer immunotherapy: A need for peripheral immunodynamic monitoring. American Journal of Reproductive Immunology, 2018, 79, e12793.	1.2	5
870	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, The, 2018, 391, 748-757.	6.3	1,142
871	Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. Journal of Thoracic Oncology, 2018, 13, 85-96.	0.5	43
872	BCG and Anti-PDL-1 Ab in Bladder Cancers. , 2018, , 357-369.		0
873	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
874	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
875	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38.	4.3	49
876	Triple-Negative Breast Cancer. , 2018, , .		0
877	Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , .	0.1	0
878	Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. Molecular Pathology Library, 2018, , 181-194.	0.1	0
879	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0

#	Article	IF	Citations
880	High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 2018, 24, 144-153.	15.2	564
881	Inhibitors of the PD-1 Pathway in Tumor Therapy. Journal of Immunology, 2018, 200, 375-383.	0.4	112
882	Genomic Assessment of Muscle-Invasive Bladder Cancer: Insights from the Cancer Genome Atlas (TCGA) Project. Molecular Pathology Library, 2018, , 43-64.	0.1	0
883	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology, 2018, 33, 62-68.	0.6	4
884	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. International Immunology, 2018, 30, 13-22.	1.8	74
885	The Basics of Cancer Immunotherapy. , 2018, , .		5
886	Genitourinary Malignancies. , 2018, , 79-94.		0
888	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. Clinical Genitourinary Cancer, 2018, 16, e961-e967.	0.9	14
889	Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends. Oncology Research and Treatment, 2018, 41, 286-290.	0.8	6
890	APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene, 2018, 37, 3924-3936.	2.6	204
891	Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy. OncoImmunology, 2018, 7, e1445952.	2.1	16
892	Pseudoprogression and hyperprogression after checkpoint blockade. International Immunopharmacology, 2018, 58, 125-135.	1.7	121
895	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 2851-2858.	3.2	65
896	A novel monoclonal antibody <scp>KMP</scp>1 has potential antitumor activity of bladder cancer by blocking <scp>CD</scp>44 in vivo and in vitro. Cancer Medicine, 2018, 7, 2064-2077.	1.3	17
897	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World Journal of Urology, 2018, 36, 1703-1709.	1.2	71
898	Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells. Endocrine-Related Cancer, 2018, 25, 533-545.	1.6	46
899	The emerging role of immunotherapy in advanced urothelial cancers. Current Opinion in Oncology, 2018, 30, 172-180.	1.1	23
900	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. European Journal of Cancer, 2018, 94, 179-186.	1.3	82

#	Article	IF	Citations
901	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecologic Oncology, 2018, 149, 381-387.	0.6	41
902	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 459-468.	0.8	8
903	T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein and Cell, 2018, 9, 254-266.	4.8	124
904	PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics, 2018, 70, 73-86.	1.2	100
905	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. Journal of Clinical Pathology, 2018, 71, 46-51.	1.0	17
906	Cancer stem cells and epithelialâ€“mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. International Journal of Urology, 2018, 25, 7-17.	0.5	48
907	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. Bioorganic and Medicinal Chemistry, 2018, 26, 2842-2849.	1.4	85
908	MicroRNAs Reprogram Tumor Immune Response. Methods in Molecular Biology, 2018, 1699, 67-74.	0.4	11
909	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. European Urology Focus, 2018, 4, 442-454.	1.6	10
910	Enhanced gastric cancer growth potential of mesenchymal stem cells derived from gastric cancer tissues educated by <scp>CD</scp>4⁺ T cells. Cell Proliferation, 2018, 51, e12399.	2.4	16
912	Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)â€“Deficient Carcinomas of the UrinaryÂSystem. Clinical Genitourinary Cancer, 2018, 16, e373-e382.	0.9	3
913	Immunotherapy for metastatic urothelial carcinoma. Current Opinion in Urology, 2018, 28, 1-7.	0.9	6
914	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. Seminars in Cancer Biology, 2018, 52, 216-227.	4.3	14
915	The diverse functions of the PD1 inhibitory pathway. Nature Reviews Immunology, 2018, 18, 153-167.	10.6	1,210
916	The application and mechanism of PD pathway blockade for cancer therapy. Postgraduate Medical Journal, 2018, 94, 53-60.	0.9	10
917	Programmed cell death ligand 1 (PDâ€Ł1) expression is not a predominant feature in Ewing sarcomas. Pediatric Blood and Cancer, 2018, 65, e26719.	0.8	39
918	PD-L1 in breast cancer: comparative analysis of 3 different antibodies. Human Pathology, 2018, 72, 28-34.	1.1	44
919	The Emerging Role of PD-1/PD-L1â€“Targeting Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma. Annals of Pharmacotherapy, 2018, 52, 60-68.	0.9	5

#	Article	IF	Citations
920	PD-L1 inhibitors in the pipeline: Promise and progress. OncoImmunology, 2018, 7, e1365209.	2.1	37
921	Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. European Urology, 2018, 73, 149-152.	0.9	93
922	Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. Cancer Letters, 2018, 414, 230-238.	3.2	63
923	Atezolizumab in urothelial bladder carcinoma. Future Oncology, 2018, 14, 331-341.	1.1	10
924	Re: Comprehensive Molecular Characterization of Muscle Invasive Bladder Cancer. European Urology, 2018, 73, 479-480.	0.9	2
925	Mechanisms of Tumor Cellâ€“Intrinsic Immune Evasion. Annual Review of Cancer Biology, 2018, 2, 213-228.	2.3	65
926	Implications of the tumor immune microenvironment for staging and therapeutics. Modern Pathology, 2018, 31, 214-234.	2.9	278
927	Product review on the Anti-PD-L1 antibody atezolizumab. Human Vaccines and Immunotherapeutics, 2018, 14, 269-276.	1.4	41
928	New developments in immunotherapy for pediatric solid tumors. Current Opinion in Pediatrics, 2018, 30, 30-39.	1.0	16
929	Antiâ€“Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. Clinical Genitourinary Cancer, 2018, 16, 117-129.	0.9	28
930	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
931	Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews Urology, 2018, 15, 92-111.	1.9	139
932	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nature Reviews Urology, 2018, 15, 112-124.	1.9	73
933	MicroRNAs Change the Landscape of Cancer Resistance. Methods in Molecular Biology, 2018, 1699, 83-89.	0.4	7
934	Pharmacokinetics and Pharmacodynamics of Immunotherapy. Current Cancer Research, 2018, , 29-67.	0.2	6
935	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. Journal of Immunology, 2018, 200, 347-354.	0.4	181
936	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. Cancer Letters, 2018, 414, 166-173.	3.2	207
937	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Laboratory Investigation, 2018, 98, 41-50.	1.7	30

#	Article	IF	Citations
938	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. Seminars in Cancer Biology, 2018, 52, 166-177.	4.3	11
939	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology, Immunotherapy, 2018, 67, 381-392.	2.0	113
940	PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. American Journal of Surgical Pathology, 2018, 42, 326-334.	2.1	38
941	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. Journal of Clinical Oncology, 2018, 36, 850-858.	0.8	288
942	The Effort in Exploration of a Definitive Predictive Factor From PD-1/PD-L1 Blockade in Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 3056-3057.	0.8	3
943	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	1.5	30
944	Implementing tumor mutational burden (TMB) analysis in routine diagnosticsâ€"a primer for molecular pathologists and clinicians. Translational Lung Cancer Research, 2018, 7, 703-715.	1.3	152
946	Using the Spleen as anIn VivoSystemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy withÎ±-PD-L1. Sarcoma, 2018, 2018, 1-13.	0.7	24
948	Subclassification, survival prediction and drug target analyses of chemotherapy-naÃ¯ve muscle-invasive bladder cancer with a molecular screening. Oncotarget, 2018, 9, 25935-25945.	0.8	22
949	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 157-172.	0.7	40
950	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Frontiers in Immunology, 2018, 9, 3081.	2.2	116
951	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
954	89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine, 2018, 24, 1852-1858.	15.2	468
955	CAR T Cell Therapy for Neuroblastoma. Frontiers in Immunology, 2018, 9, 2380.	2.2	107
956	Harnessing immune checkpoints for cancer therapy. Immunotherapy, 2018, 10, 1265-1284.	1.0	9
957	Î²catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC Cancer, 2018, 18, 1062.	1.1	20
958	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Current Oncology, 2018, 25, 373-384.	0.9	109
959	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. Journal of Oncology, 2018, 2018, 1-14.	0.6	44

#	Article	IF	Citations
960	Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight, 2018, 3, .	2.3	40
961	The promise of immunotherapy in genitourinary malignancies. Precision Clinical Medicine, 2018, 1, 97-101.	1.3	4
962	Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Frontiers in Immunology, 2018, 9, 2821.	2.2	76
963	Predicting Response to Intravesical Therapy in Nonâ€“muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 494-502.	1.6	8
964	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Scientific Reports, 2018, 8, 17812.	1.6	39
965	Progress of immune checkpoint therapy in the clinic (Review). Oncology Reports, 2019, 41, 3-14.	1.2	24
966	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infectionâ€”A Mini Comment on the 2018 Medicine Nobel Prize. Virologica Sinica, 2018, 33, 467-471.	1.2	9
967	The continuing role of chemotherapy in the management of advanced urothelial cancer. Therapeutic Advances in Urology, 2018, 10, 455-480.	0.9	16
968	Immune checkpoint inhibitors in cancer therapy. Journal of Biomedical Research, 2018, 32, 317.	0.7	101
969	PD-1 Blockade Overcomes Adaptive Immune Resistance in Treatment with Anchored-GM-CSF Bladder Cancer Cells Vaccine. Journal of Cancer, 2018, 9, 4374-4381.	1.2	5
970	Prime time for immunotherapy in advanced urothelial cancer. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 24-32.	0.7	2
971	The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. Journal of Translational Medicine, 2018, 16, 273.	1.8	73
972	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
973	From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. European Urology Oncology, 2018, 1, 486-500.	2.6	35
974	The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release, 2018, 290, 28-45.	4.8	67
975	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
976	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. OncoImmunology, 2018, 7, e1494112.	2.1	29
977	Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS ONE, 2018, 13, e0205746.	1.1	38

#	Article	IF	Citations
978	Current Clinical Trials in Non-muscle Invasive Bladder Cancer. Current Urology Reports, 2018, 19, 101.	1.0	28
979	Hypothalamitis and severe hypothalamic dysfunction associated with antiâ€“programmed cell death ligand 1 antibody treatment. European Journal of Cancer, 2018, 104, 247-249.	1.3	20
980	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE, 2018, 13, e0206223.	1.1	149
981	Overexpression of long nonâ€coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis. Molecular Medicine Reports, 2018, 18, 5437-5444.	1.1	6
982	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 2018, 13, 1906-1918.	0.5	88
983	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. Journal of Gynecologic Oncology, 2018, 29, e93.	1.0	37
984	Bladder cancer: overview and management. Part 2: muscle-invasive and metastatic bladder cancer. British Journal of Nursing, 2018, 27, S8-S20.	0.3	14
985	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature Communications, 2018, 9, 4297.	5.8	101
987	An assessment of prognostic immunity markers in breast cancer. Npj Breast Cancer, 2018, 4, 35.	2.3	41
988	PD-L1 on host cells is essential for PD-L1 blockadeâ€mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 580-588.	3.9	388
989	Management of High-grade T1 Urothelial Carcinoma. Current Urology Reports, 2018, 19, 103.	1.0	7
990	Radiopharmacology and molecular imaging of PD-L1 expression in cancer. Clinical and Translational Imaging, 2018, 6, 429-439.	1.1	7
991	Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Annals of Oncology, 2018, 29, 2247-2253.	0.6	101
993	T Cell Senescence and Tumor Immunotherapy. , 2018, , 1-24.		0
994	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31
995	Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. OncoImmunology, 2018, 7, e1476816.	2.1	32
996	Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Antibody Therapeutics, 2018, 1, 65-73.	1.2	25
997	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer, 2018, 103, 7-16.	1.3	63

#	Article	IF	Citations
998	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs, 2018, 10, 1301-1311.	2.6	57
999	Chemotherapy Combines Effectively with Antiâ€“PD-L1 Treatment and Can Augment Antitumor Responses. Journal of Immunology, 2018, 201, 2273-2286.	0.4	38
1000	Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008-2015. Clinical Genitourinary Cancer, 2018, 16, e1171-e1179.	0.9	18
1002	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127
1003	The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. Cancer Treatment and Research, 2018, 175, 193-214.	0.2	3
1004			

#	Article	IF	Citations
1019	Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types. OncoImmunology, 2018, 7, e1466018.	2.1	51
1020	A mathematical model of cytotoxic and helper T cell interactions in a tumour microenvironment. Letters in Biomathematics, 2018, 5, S36-S68.	0.3	12
1021	Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. Human Pathology, 2018, 80, 170-178.	1.1	40
1022	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. Bladder Cancer, 2018, 4, 9-18.	0.2	18
1023	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	1.0	12
1024	Basalâ€subtype bladder tumours show a â€˜hotâ€™ immunophenotype. Histopathology, 2018, 73, 748-757.	1.6	43
1025	Expression and clinical significance of PDâ€1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PDâ€1 monoclonal antibody. International Journal of Oncology, 2018, 52, 2079-2092.	1.4	10
1026	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. BMC Cancer, 2018, 18, 652.	1.1	13
1027	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. Bladder Cancer, 2018, 4, 429-440.	0.2	5
1028	Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. , 2018, 6, 35.		172
1029	Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective. Current Oncology, 2018, 25, 209-216.	0.9	34
1030	Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1â€“CH3 fusion protein. Cancer Immunology, Immunotherapy, 2018, 67, 1621-1634.	2.0	46
1031	Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2018, 140, 317-328.	1.4	107
1032	The use of SAMe in chemotherapy-induced liver injury. Critical Reviews in Oncology/Hematology, 2018, 130, 70-77.	2.0	21
1033	Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. Journal of Controlled Release, 2018, 286, 369-380.	4.8	70
1034	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. Theranostics, 2018, 8, 3559-3570.	4.6	85
1035	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. Journal of Cancer, 2018, 9, 1200-1206.	1.2	31
1036	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1019-1040.	0.9	55

#	Article	IF	Citations
1037	Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy. European Urology, 2018, 74, 540-544.	0.9	53
1038	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. European Urology, 2018, 74, 741-753.	0.9	54
1039	Construction of an antiâ€'programmed deathâ€'ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. Oncology Letters, 2018, 16, 157-166.	0.8	9
1040	The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by Î±-PD-L1 or Î±-IL6 antibodies. Journal of Leukocyte Biology, 2018, 104, 969-985.	1.5	12
1041	The value of neutrophil-to-lymphocyte ratio for response and prognostic effect of neoadjuvant chemotherapy in solid tumors: A systematic review and meta-analysis. Journal of Cancer, 2018, 9, 861-871.	1.2	47
1042	Immune Checkpoint Blockade in Hematologic Malignancies. , 2018, , 1583-1587.		1
1043	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212.	1.2	9
1044	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer, 2018, 101, 201-209.	1.3	41
1045	Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature. SAGE Open Medical Case Reports, 2018, 6, 2050313X1879242.	0.2	26
1047	Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma. Frontiers in Oncology, 2018, 8, 71.	1.3	22
1048	Concordance of PD-L1 expression in matched urothelial bladder cancer specimens. Histopathology, 2018, 73, 983-989.	1.6	24
1049	DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. Viruses, 2018, 10, 82.	1.5	82
1050	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers, 2018, 10, 39.	1.7	44
1051	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Seminars in Cancer Biology, 2018, 52, 151-157.	4.3	108
1052	PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations. International Journal of Molecular Sciences, 2018, 19, 1984.	1.8	31
1053	Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature Reviews Urology, 2018, 15, 615-625.	1.9	284
1054	Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Clinical Cancer Research, 2018, 24, 6115-6124.	3.2	14
1055	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698.	2.8	39

#	Article	IF	Citations
1056	Microbial biomarkers for immune checkpoint blockade therapy against cancer. Journal of Gastroenterology, 2018, 53, 999-1005.	2.3	15
1057	Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma. Nature Reviews Urology, 2018, 15, 585-587.	1.9	28
1058	Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors. Diagnostic Pathology, 2018, 13, 30.	0.9	43
1059	PD-L1⁺ tumor-associated macrophages and PD-1⁺ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma. Haematologica, 2018, 103, 1908-1914.	1.7	64
1060	PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma. American Journal of Surgical Pathology, 2018, 42, 1059-1066.	2.1	79
1061	PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. American Journal of Dermatopathology, 2018, 40, 647-654.	0.3	42
1062	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
1063	Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?. Cell and Bioscience, 2018, 8, 34.	2.1	83
1064	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
1065	Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer. BMC Cancer, 2018, 18, 194.	1.1	18
1066	Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36. Journal of Biosciences, 2018, 43, 365-373.	0.5	25
1068	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
1069	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
1070	Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. OncoImmunology, 2018, 7, e1465165.	2.1	59
1071	A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer, 2018, 4, 269-282.	0.2	6
1072	Human cancer evolution in the context of a human immune system in mice. Molecular Oncology, 2018, 12, 1797-1810.	2.1	11
1073	New insights into the pathogenesis and treatment of non-viral hepatocellular carcinoma: a balancing act between immunosuppression and immunosurveillance. Precision Clinical Medicine, 2018, 1, 21-28.	1.3	16
1074	Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clinical Cancer Research, 2018, 24, 6212-6222.	3.2	168

#	Article	IF	Citations
1075	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology, 2018, 36, 847-856.	9.4	564
1076	Mouse models in the era of large human tumour sequencing studies. Open Biology, 2018, 8, .	1.5	7
1077	Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects. ACS Nano, 2018, 12, 8308-8322.	7.3	213
1078	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines, 2018, 6, 87.	1.4	8
1079	Highâ€affinity <scp>PD</scp>â€1 molecules deliver improved interaction with <scp>PD</scp>â€L1 and <scp>PD</scp>â€L2. Cancer Science, 2018, 109, 2435-2445.	1.7	21
1080	Preliminary application of 125Iâ€“nivolumab to detect PD-1 expression in colon cancer via SPECT. Journal of Radioanalytical and Nuclear Chemistry, 2018, 318, 1237-1242.	0.7	7
1081	Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy. Molecular Pharmaceutics, 2018, 15, 4426-4433.	2.3	37
1082	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nature Medicine, 2018, 24, 724-730.	15.2	637
1083	Pourquoi lâ€™urologue doit sâ€™intÃ©resser Ã lâ€™immunothÃ©rapie, quelles sont les indications Ã©tablies en 2018Âet celles en perspectivesÂ?. ProgrÃ¨s En Urologie - FMC, 2018, 28, F26-F29.	0.2	0
1084	PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunology Research, 2018, 6, 921-929.	1.6	133
1085	Immune checkpoint inhibition in gastric cancer: A systematic review. Journal of Cellular Immunotherapy, 2018, 4, 49-55.	0.6	7
1086	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. Mayo Clinic Proceedings, 2018, 93, 917-936.	1.4	4
1087	Cancer immunotherapy: broadening the scope of targetable tumours. Open Biology, 2018, 8, .	1.5	162
1088	Clinical relevance of <scp>PD</scp>â€L1 expression in gallbladder cancer: a potential target for therapy. Histopathology, 2018, 73, 622-633.	1.6	31
1089	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discovery, 2018, 8, 944-957.	7.7	313
1090	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Current Medicinal Chemistry, 2018, 25, 1327-1339.	1.2	99
1091	Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. Liver Cancer, 2019, 8, 110-120.	4.2	46
1092	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	2.3	8

#	Article	IF	Citations
1093	A <scp>PK/PD</scp> Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumabâ€Treated nonâ€small Cell Lung Cancer Patients. Clinical Pharmacology and Therapeutics, 2019, 105, 486-495.	2.3	23
1094	Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut, 2019, 68, 1024-1033.	6.1	120
1095	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405.	2.6	149
1096	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cellular and Molecular Immunology, 2019, 16, 28-39.	4.8	57
1097	Cancer immunotherapy for metastasis: past, present and future. Briefings in Functional Genomics, 2019, 18, 140-146.	1.3	10
1098	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. Journal of Oncology Pharmacy Practice, 2019, 25, 663-673.	0.5	8
1099	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Advances in Therapy, 2019, 36, 2638-2678.	1.3	145
1100	PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors. , 2019, 7, 217.		47
1101	Long Noncoding RNA MIR17HG Promotes Colorectal Cancer Progression via miR-17-5p. Cancer Research, 2019, 79, 4882-4895.	0.4	157
1102	Realâ€world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced nonâ€“small cell lung cancer. Cancer, 2019, 125, 4019-4032.	2.0	115
1103	Metastatic Bladder Cancer Disease and Its Treatment. , 2019, , 403-411.		0
1104	Bifurcation analyses and hormetic effects of a discrete-time tumor model. Applied Mathematics and Computation, 2019, 363, 124618.	1.4	4
1105	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell, 2019, 36, 168-178.e4.	7.7	240
1106	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
1107	A co-expression network for differentially expressed genes in bladder cancer and a risk score model for predicting survival. Hereditas, 2019, 156, 24.	0.5	20
1108	Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 2019, 16, 465-483.	1.9	119
1109	Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells. Food and Chemical Toxicology, 2019, 132, 110693.	1.8	26
1110	The Mechanism of Antiâ€“PD-L1 Antibody Efficacy against PD-L1â€“Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector. Cancer Discovery, 2019, 9, 1422-1437.	7.7	210

#	Article	IF	Citations
1111	Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway. Bioscience Reports, 2019, 39, .	1.1	40
1112	CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis. Bladder Cancer, 2019, 5, 159-169.	0.2	5
1113	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer1. Bladder Cancer, 2019, 5, 131-145.	0.2	11
1114	Characterization and Comparison of GITR Expression in Solid Tumors. Clinical Cancer Research, 2019, 25, 6501-6510.	3.2	37
1115	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. Cancers, 2019, 11, 872.	1.7	50
1116	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology, 2019, 10, 1337.	2.2	85
1117	PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma. Biochemical and Biophysical Research Communications, 2019, 516, 983-990.	1.0	12
1119	Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 599-608.	1.4	45
1120	Alternative dosing regimens for atezolizumab: right dose, wrong frequency. Cancer Chemotherapy and Pharmacology, 2019, 84, 1153-1155.	1.1	20
1121	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers, 2019, 11, 1554.	1.7	73
1122	The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Frontiers in Oncology, 2019, 9, 897.	1.3	29
1123	Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Scientific Reports, 2019, 9, 14356.	1.6	56
1124	Fucosylated Î±1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. Scientific Reports, 2019, 9, 14503.	1.6	16
1125	Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagnostic Pathology, 2019, 14, 99.	0.9	41
1126	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Seminars in Immunology, 2019, 42, 101295.	2.7	16
1127	Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Journal of Oncology, 2019, 2019, 1-11.	0.6	6
1128	Road map to best practices. , 2019, , 241-273.		2
1129	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. Critical Reviews in Oncology/Hematology, 2019, 144, 102812.	2.0	7

#	Article	IF	Citations
1130	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. International Journal of Molecular Sciences, 2019, 20, 5452.	1.8	53
1131	Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 4194-4201.	1.9	6
1132	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
1133	PD-1-Targeted Discovery of Peptide Inhibitors by Virtual Screening, Molecular Dynamics Simulation, and Surface Plasmon Resonance. Molecules, 2019, 24, 3784.	1.7	26
1134	Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet. Frontiers in Genetics, 2019, 10, 1125.	1.1	28
1135	Tollâ€like receptors: The role in bladder cancer development, progression and immunotherapy. Scandinavian Journal of Immunology, 2019, 90, e12818.	1.3	46
1136	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes and Diseases, 2019, 6, 232-246.	1.5	44
1137	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research, 2019, 25, 6061-6072.	3.2	58
1138	PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. , 2019, 7, 228.		26
1139	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. International Journal of Molecular Sciences, 2019, 20, 4263.	1.8	17
1140	Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. International Immunopharmacology, 2019, 76, 105866.	1.7	26
1141	PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma. OncoImmunology, 2019, 8, e1655362.	2.1	39
1142	Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. Journal of Hematology and Oncology, 2019, 12, 92.	6.9	485
1143	Circulating biomarkers predictive of tumor response to cancer immunotherapy. Expert Review of Molecular Diagnostics, 2019, 19, 895-904.	1.5	28
1144	Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC. Molecular Therapy, 2019, 27, 1906-1918.	3.7	35
1145	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. Russian Journal of Bioorganic Chemistry, 2019, 45, 225-240.	0.3	6
1146	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Journal of Clinical Investigation, 2019, 129, 2056-2070.	3.9	159
1147	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. Matter, 2019, 1, 1331-1353.	5.0	78

#	Article	IF	Citations
1148	The multifaceted immune regulation of bladder cancer. Nature Reviews Urology, 2019, 16, 613-630.	1.9	123
1149	Mapping the Binding Hot Spots on Human Programmed Cell Death 1 and Its Ligand with Free-Energy Simulations. Journal of Chemical Information and Modeling, 2019, 59, 4339-4349.	2.5	4
1150	HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 13404.	1.6	103
1151	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654.	1.8	29
1152	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 505-510.	0.6	30
1153	Rhein Augments Antiproliferative Effects of Atezolizumab Based on Breast Cancer (4T1) Regression. Planta Medica, 2019, 85, 1143-1149.	0.7	14
1154	Antibody-mediated targeting of TNFR2 activates CD8 ⁺ T cells in mice and promotes antitumor immunity. Science Translational Medicine, 2019, 11, .	5.8	39
1155	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. Cancer Microenvironment, 2019, 12, 119-132.	3.1	46
1156	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemotherapy and Pharmacology, 2019, 84, 1257-1267.	1.1	58
1157	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. Frontiers in Immunology, 2019, 10, 2310.	2.2	26
1158	The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG). Targeted Oncology, 2019, 14, 15-32.	1.7	12
1159	Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis. Seminars in Oncology, 2019, 46, 65-72.	0.8	14
1160	Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report. Drug Design, Development and Therapy, 2019, Volume 13, 291-300.	2.0	14
1161	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro-Oncology, 2019, 21, 730-741.	0.6	63
1162	Antiâ€“PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment. Cancer Research, 2019, 79, 1493-1506.	0.4	118
1163	Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 848-854.	3.3	60
1164	SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine, 2019, 40, 151-162.	2.7	53
1165	PDâ€1/PDâ€L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. Cell Proliferation, 2019, 52, e12571.	2.4	94

#	Article	IF	Citations
1166	Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma . Cancer Management and Research, 2019, Volume 11, 4519-4528.	0.9	11
1167	Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis . Cancer Management and Research, 2019, Volume 11, 4171-4184.	0.9	31
1168	Liquid biopsy for lung cancer immunotherapy (Review). Oncology Letters, 2019, 17, 4751-4760.	0.8	14
1169	Clinical Development of FGFR3 Inhibitors for the Treatment of Urothelial Cancer. Bladder Cancer, 2019, 5, 87-102.	0.2	10
1170	Recent advances in the clinical development of immune checkpoint blockade therapy. Cellular Oncology (Dordrecht), 2019, 42, 609-626.	2.1	76
1171	Long non-coding RNA DILC suppresses bladder cancer cells progression. Gene, 2019, 710, 193-201.	1.0	11
1172	USP13 functions as a tumor suppressor by blocking the NF-kB-mediated PTEN downregulation in human bladder cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 259.	3.5	70
1173	Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status. Journal of Cancer, 2019, 10, 1745-1754.	1.2	19
1174	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. Cancer Discovery, 2019, 9, 1208-1227.	7.7	81
1175	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. Diagnostic Pathology, 2019, 14, 62.	0.9	4
1176	The 100 top-cited studies in cancer immunotherapy. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 2282-2292.	1.9	26
1177	Ras-association domain family 1 (RASSF1A) gene regulates progression, migration and invasion of bladder cancer. Surgical Oncology, 2019, 30, 63-71.	0.8	6
1178	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. Cancers, 2019, 11, 754.	1.7	21
1179	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. Journal of Hematology and Oncology, 2019, 12, 54.	6.9	416
1180	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. International Journal of Biological Sciences, 2019, 15, 919-928.	2.6	21
1181	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. European Urology, 2019, 76, 782-789.	0.9	38
1182	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	4.2	125
1183	Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 924-937.	5.1	1,133

#	Article	IF	Citations
1184	Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8+ T Cells in Murine Syngeneic Tumor Models. Cancer Immunology Research, 2019, 7, 963-976.	1.6	36
1185	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Clinical Cancer Research, 2019, 25, 4808-4819.	3.2	66
1186	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. Journal of Pathology, 2019, 249, 151-165.	2.1	80
1187	Computational analysis of hot spots and binding mechanism in the PD-1/PD-L1 interaction. RSC Advances, 2019, 9, 14944-14956.	1.7	23
1188	The Discovery of Biomarkers in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 2019, 17, 484-497.	1.9	31
1189	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. Pathology Research and Practice, 2019, 215, 152402.	1.0	11
1190	Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses. Science, 2019, 364, 558-566.	6.0	262
1191	Efficient evolved antibody mimetic designed ankyrin repeat proteins against programmed death-ligand 1 on E. coli surface display. Biochemical Engineering Journal, 2019, 148, 1-8.	1.8	1
1192	Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab. Molecular Imaging, 2019, 18, 153601211982998.	0.7	55
1193	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 1405.	1.8	36
1194	Hope and challenge: Precision medicine in bladder cancer. Cancer Medicine, 2019, 8, 1806-1816.	1.3	34
1195	Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma. Cancer Immunology Research, 2019, 7, 805-812.	1.6	22
1196	A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer . OncoTargets and Therapy, 2019, Volume 12, 1791-1801.	1.0	20
1197	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines and Immunotherapeutics, 2019, 15, 1111-1122.	1.4	297
1198	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist, 2019, 24, S11-S20.	1.9	2
1199	Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. European Urology, 2019, 76, 4-6.	0.9	8
1200	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450.	1.5	32
1201	lncRNA CASC11 promotes cancer cell proliferation in bladder cancer through miRNAâ€150. Journal of Cellular Biochemistry, 2019, 120, 13487-13493.	1.2	92

#	Article	IF	Citations
1202	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. European Urology, 2019, 76, 73-81.	0.9	117
1203	Targeting immune cells for cancer therapy. Redox Biology, 2019, 25, 101174.	3.9	151
1204	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Annals of Oncology, 2019, 30, 1134-1142.	0.6	113
1205	Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. Translational Medicine Communications, 2019, 4, .	0.5	3
1206	RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. EBioMedicine, 2019, 41, 146-155.	2.7	31
1207	Prognostic value of PD-L1 expression in patients with pancreatic cancer. Medicine (United States), 2019, 98, e14006.	0.4	30
1208	Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investigative and Clinical Urology, 2019, 60, 64.	1.0	12
1209	Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity. International Immunopharmacology, 2019, 70, 498-503.	1.7	21
1210	Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Scientific Reports, 2019, 9, 4532.	1.6	64
1211	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immunotherapy, 2019, 11, 515-529.	1.0	17
1212	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1651-1660.	1.2	31
1213	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer, 2019, 26, R31-R52.	1.6	49
1214	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. Molecules, 2019, 24, 1190.	1.7	163
1215	Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification. , 2019, 7, 86.		11
1216	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	3.9	43
1217	Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis . Drug Design, Development and Therapy, 2019, Volume 13, 523-538.	2.0	23
1218	Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy. Journal of Pathology, 2019, 248, 230-242.	2.1	32
1219	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Modern Pathology, 2019, 32, 1053-1064.	2.9	40

#	Article	IF	Citations
1220	PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. OncoImmunology, 2019, 8, e1544442.	2.1	51
1221	Turning the corner on therapeutic cancer vaccines. Npj Vaccines, 2019, 4, 7.	2.9	490
1222	Impact of Immunotherapy after Resection of Pancreatic Cancer. Journal of the American College of Surgeons, 2019, 229, 19-27.e1.	0.2	11
1223	Bacillus Calmette-GuÃ©rin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 17-30.	3.9	20
1224	Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma. Current Oncology Reports, 2019, 21, 24.	1.8	16
1225	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	1.0	9
1226	PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers, 2019, 11, 232.	1.7	43
1227	Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus. Viruses, 2019, 11, 156.	1.5	32
1228	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. Cancer Reports, 2019, 2, e1160.	0.6	26
1231	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. Immunity, 2019, 51, 1059-1073.e9.	6.6	229
1232	Computational STAT3 activity inference reveals its roles in the pancreatic tumor microenvironment. Scientific Reports, 2019, 9, 18257.	1.6	7
1233	Facial Palsy Induced by Checkpoint Blockade: A Single Center Retrospective Study. Journal of Immunotherapy, 2019, 42, 94-96.	1.2	9
1234	Is the extirpative surgery for primary tumor helpful for the patients with metastatic urothelial cancer at the time of diagnosis?. Medicine (United States), 2019, 98, e15930.	0.4	3
1235	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Frontiers in Pharmacology, 2019, 10, 1350.	1.6	75
1236	Targeting advanced urothelial carcinoma-developing strategies. Current Opinion in Oncology, 2019, 31, 207-215.	1.1	14
1237	In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles. Nature Biotechnology, 2019, 37, 1322-1331.	9.4	398
1238	Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nature Immunology, 2019, 20, 1425-1434.	7.0	336
1239	Developing neoantigen-targeted T cellâ€“based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173

#	Article	IF	Citations
1240	Hyperthermia and immunotherapy: clinical opportunities. International Journal of Hyperthermia, 2019, 36, 4-9.	1.1	51
1241	Tumor-suppressor microRNA-139-5p restrains bladder cancer cell line ECV-304 properties via targeting Connexin 43. Chinese Medical Journal, 2019, 132, 2354-2361.	0.9	11
1242	Epidermal growth factor receptor stabilizes programmed death ligand 1 by glycosylation in colorectal cancer with microstatellite instability status. Journal of Bio-X Research, 2019, 2, 1-8.	0.3	1
1243	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 355-364.	2.6	25
1244	The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 879.	1.3	6
1245	Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591989028.	1.4	74
1246	Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacyâ€"A Systematic Review. Current Oncology, 2019, 26, 395-403.	0.9	44
1247	Molecular characterization of cancers with NTRK gene fusions. Modern Pathology, 2019, 32, 147-153.	2.9	360
1248	PDâ€1/PDâ€L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology, 2019, 234, 1313-1325.	2.0	288
1249	Immune Checkpoints. , 2019, , 19-43.		0
1250	Urologic Malignancies. , 2019, , 115-133.		0
1251	MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. Journal of Drug Targeting, 2019, 27, 67-74.	2.1	49
1252	Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. European Urology, 2019, 75, 423-432.	0.9	205
1253	Combined Î±-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma. Cancer Biology and Therapy, 2019, 20, 666-679.	1.5	6
1254	Programmed death ligandâ€1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Science, 2019, 110, 489-498.	1.7	66
1255	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
1256	Molecular profiling in muscleâ€invasive bladder cancer: more than the sum of its parts. Journal of Pathology, 2019, 247, 563-573.	2.1	63
1257	The complicated effects ofÂ obesity on cancer and immunotherapy. Immunotherapy, 2019, 11, 11-14.	1.0	10

#	Article	IF	Citations
1258	<scp>PD</scp>â€L1 and <scp>IDO</scp> expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy. Histopathology, 2019, 74, 256-268.	1.6	42
1259	Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis. Cancer Biology and Therapy, 2019, 20, 552-561.	1.5	29
1260	The clinical role of the TME in solid cancer. British Journal of Cancer, 2019, 120, 45-53.	2.9	380
1261	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nature Medicine, 2019, 25, 141-151.	15.2	539
1262	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and realâ€life analysis of three larger gene panels. International Journal of Cancer, 2019, 144, 2303-2312.	2.3	95
1263	NOTCH1 regulates the proliferation and migration of bladder cancer cells by cooperating with long nonâ€coding RNA HCG18 and microRNAâ€34câ€5p. Journal of Cellular Biochemistry, 2019, 120, 6596-6604.	1.2	43
1264	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Archives of Pathology and Laboratory Medicine, 2019, 143, 722-731.	1.2	22
1265	Treatment of Metastatic Bladder Cancer. , 2019, , 123-137.		0
1266	Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 299.e19-299.e25.	0.8	30
1267	Management of Urothelial Carcinoma. , 2019, , .		0
1268	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474.	1.4	16
1269	Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 290.e17-290.e24.	0.8	13
1270	Intravesical BCG: where do we stand? Past, present and future. Journal of Clinical Urology, 2019, 12, 425-435.	0.1	1
1271	Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 16.	3.5	27
1272	Recent advances in upper tract urothelial carcinomas: From bench to clinics. International Journal of Urology, 2019, 26, 148-159.	0.5	19
1273	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. World Journal of Urology, 2019, 37, 1773-1784.	1.2	22
1274	Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma. OncoImmunology, 2019, 8, e1507669.	2.1	41
1275	Expression of PDâ€L1 in tumorâ€associated nerves correlates with reduced CD8⁺ tumorâ€associated lymphocytes and poor prognosis in prostate cancer. International Journal of Cancer, 2019, 144, 3099-3110.	2.3	45

#	Article	IF	Citations
1276	Phenotypic Analysis of Tumor Tissueâ€“Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 114-124.	0.9	8
1277	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	1.3	75
1278	Whatâ€™s New in Dermatopathology: Inflammatory Dermatoses. Advances in Anatomic Pathology, 2019, 26, 40-55.	2.4	2
1279	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of nonâ€muscleâ€invasive disease. BJU International, 2019, 123, 947-958.	1.3	9
1280	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. Annual Review of Cancer Biology, 2019, 3, 385-408.	2.3	17
1281	CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status. Clinical Cancer Research, 2019, 25, 390-402.	3.2	44
1282	Size matters: Dissecting key parameters for panelâ€based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
1283	PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Human Pathology, 2019, 84, 291-298.	1.1	18
1284	FcÎ³R interaction is not required for effective antiâ€PDâ€L1 immunotherapy but can add additional benefit depending on the tumor model. International Journal of Cancer, 2019, 144, 345-354.	2.3	12
1285	BOXITâ€”A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology, 2019, 75, 593-601.	0.9	27
1286	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro-Oncology, 2019, 21, 95-105.	0.6	100
1287	Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 92-100.	0.6	144
1288	Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cellular and Molecular Immunology, 2019, 16, 401-409.	4.8	105
1289	Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Seminars in Cancer Biology, 2020, 64, 29-35.	4.3	76
1290	The emerging role of epigenetic therapeutics in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 75-90.	12.5	260
1291	Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharmaceutica Sinica B, 2020, 10, 358-373.	5.7	61
1292	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharmaceutica Sinica B, 2020, 10, 723-733.	5.7	102
1293	Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Annals of Surgical Oncology, 2020, 27, 599-607.	0.7	33

#	Article	IF	Citations
1294	PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials. International Journal of Surgical Pathology, 2020, 28, 31-37.	0.4	5
1295	How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-GuÃ©rin?. European Urology Oncology, 2020, 3, 252-257.	2.6	1
1296	Interâ€•and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology, 2020, 76, 191-200.	1.6	35
1297	Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 38, 1517-1524.	1.2	8
1298	Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 535-542.	1.4	8
1299	Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-Î³ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. Cancer Biology and Therapy, 2020, 21, 130-138.	1.5	6
1300	Multiâ€•omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. Journal of Cellular Physiology, 2020, 235, 3849-3863.	2.0	32
1301	Clinical outcome after progressing to frontline and second-line Antiâ€“PD-1/PD-L1 in advanced urothelial cancer. European Urology, 2020, 77, 269-276.	0.9	45
1302	A Nanoscale Metalâ€“Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. Angewandte Chemie, 2020, 132, 1124-1128.	1.6	34
1303	Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. Molecular Cancer Therapeutics, 2020, 19, 270-281.	1.9	11
1304	A Nanoscale Metalâ€“Organic Framework to Mediate Photodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Enhance Antigen Presentation and Cancer Immunotherapy. Angewandte Chemie - International Edition, 2020, 59, 1108-1112.	7.2	144
1305	Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor Î² complementarity-determining region 3. Journal of Immunological Methods, 2020, 476, 112679.	0.6	3
1306	Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncology, 2020, 16, 4439-4453.	1.1	29
1307	Depletion of CDC5L inhibits bladder cancer tumorigenesis. Journal of Cancer, 2020, 11, 353-363.	1.2	25
1308	The renal adverse effects of cancer immunotherapy. Journal of Nephrology, 2020, 33, 467-481.	0.9	6
1309	Current issues and perspectives in PD-1 blockade cancer immunotherapy. International Journal of Clinical Oncology, 2020, 25, 790-800.	1.0	120
1310	iRECIST: how to do it. Cancer Imaging, 2020, 20, 2.	1.2	41
1311	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 2020, 39, 26-35.	0.9	69

#	Article	IF	Citations
1312	Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. American Journal of Surgical Pathology, 2020, 44, 378-386.	2.1	23
1313	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. Cancer Treatment Reviews, 2020, 82, 101925.	3.4	73
1314	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry, 2020, 186, 111876.	2.6	98
1315	Immuno-Oncology Approaches to Salvage Treatment for Non-muscle invasive Bladder Cancer. Urologic Clinics of North America, 2020, 47, 103-110.	0.8	11
1316	A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Molecular Imaging and Biology, 2020, 22, 842-853.	1.3	16
1317	Programmed Cell Death-1/Ligand-1 PET Imaging. PET Clinics, 2020, 15, 35-43.	1.5	34
1318	Infiltration of tumorâ€associated macrophages is involved in tumor programmed deathâ€ligand 1 expression in early lung adenocarcinoma. Cancer Science, 2020, 111, 727-738.	1.7	34
1319	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. Cellular and Molecular Life Sciences, 2020, 77, 3441-3452.	2.4	22
1320	Mechanisms of immune evasion in bladder cancer. Cancer Immunology, Immunotherapy, 2020, 69, 3-14.	2.0	127
1321	Diselenideâ€“Pemetrexed Assemblies for Combined Cancer Immunoâ€, Radioâ€, and Chemotherapies. Angewandte Chemie, 2020, 132, 2722-2726.	1.6	11
1322	Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Journal of Immunotherapy, 2020, 43, 121-133.	1.2	15
1323	DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 1449-1459.	3.2	16
1324	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. British Journal of Cancer, 2020, 122, 94-101.	2.9	35
1325	Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast. Applied Immunohistochemistry and Molecular Morphology, 2020, 28, 661-668.	0.6	7
1326	Bacillus Calmetteâ€“GuÃ©rinâ€unresponsive nonâ€muscleâ€invasive bladder cancer: Its definition and future therapeutic strategies. International Journal of Urology, 2020, 27, 108-116.	0.5	22
1327	Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level. International Immunopharmacology, 2020, 78, 106077.	1.7	29
1328	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. Pathology and Oncology Research, 2020, 26, 651-663.	0.9	18
1329	Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma. World Neurosurgery, 2020, 135, e187-e193.	0.7	19

#	Article	IF	Citations
1330	Diselenideâ€“Pemetrexed Assemblies for Combined Cancer Immunoâ€; Radioâ€; and Chemotherapies. Angewandte Chemie - International Edition, 2020, 59, 2700-2704.	7.2	100
1331	Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy. Science Advances, 2020, 6, .	4.7	49
1332	Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer. Cancer Letters, 2020, 495, 1-11.	3.2	13
1333	Using phage-assisted continuous evolution (PACE) to evolve human PD1. Experimental Cell Research, 2020, 396, 112244.	1.2	3
1334	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. European Journal of Cancer, 2020, 138, 202-211.	1.3	19
1335	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. Urologic Clinics of North America, 2020, 47, 487-510.	0.8	10
1336	A drug safety evaluation of atezolizumab in locally advanced or metastatic urothelial carcinoma. Expert Opinion on Drug Safety, 2020, 19, 955-960.	1.0	3
1338	Analysis of singleâ€cell RNAseq identifies transitional states of T cells associated with hepatocellular carcinoma. Clinical and Translational Medicine, 2020, 10, e133.	1.7	17
1339	Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma. Frontiers in Molecular Biosciences, 2020, 7, 602328.	1.6	30
1340	Identification of Sex Differences in Tumor-Specific T Cell Infiltration in Bladder Tumor-Bearing Mice Treated with BCG Immunotherapy. Bladder Cancer, 2020, 6, 507-524.	0.2	3
1341	The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells . OncoTargets and Therapy, 2020, Volume 13, 12225-12241.	1.0	5
1342	Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma. Frontiers in Oncology, 2020, 10, 555757.	1.3	12
1343	Identification of immune-related genes as prognostic factors in bladder cancer. Scientific Reports, 2020, 10, 19695.	1.6	15
1344	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. Archivum Immunologiae Et Therapiae Experimentalis, 2020, 68, 36.	1.0	26
1345	A phase 2 trial of buparlisib in patients with platinumâ€resistant metastatic urothelial carcinoma. Cancer, 2020, 126, 4532-4544.	2.0	14
1346	A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis. International Immunopharmacology, 2020, 87, 106851.	1.7	12
1347	Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. Journal of Translational Medicine, 2020, 18, 303.	1.8	11
1348	Phospholipase C-like protein 2 (PLC-L2) is associated with cytolytic ability of CD8⁺ T cells and prognosis of prostate cancer. Materials Express, 2020, 10, 725-732.	0.2	0

#	Article	IF	Citations
1349	Myeloid Cells as Clinical Biomarkers for Immune Checkpoint Blockade. Frontiers in Immunology, 2020, 11, 1590.	2.2	50
1350	Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?. Frontiers in Oncology, 2020, 10, 1193.	1.3	13
1351	Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. Npj Breast Cancer, 2020, 6, 29.	2.3	26
1352	Identification of 9-Core Immune-Related Genes in Bladder Urothelial Carcinoma Prognosis. Frontiers in Oncology, 2020, 10, 1142.	1.3	18
1353	Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Frontiers in Immunology, 2020, 11, 2039.	2.2	187
1354	Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy. Tumori, 2020, 107, 030089162094038.	0.6	8
1356	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nature Reviews Cancer, 2020, 20, 662-680.	12.8	860
1357	3D bioprinting for reconstituting the cancer microenvironment. Npj Precision Oncology, 2020, 4, 18.	2.3	163
1358	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinumâ€resistant metastatic urothelial cancer. Cancer, 2020, 126, 4485-4497.	2.0	24
1359	Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncology, 2020, 16, 1707-1713.	1.1	11
1360	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. Biomolecules, 2020, 10, 1061.	1.8	59
1361	Non-Conventional Treatments for Conventional Chondrosarcoma. Cancers, 2020, 12, 1962.	1.7	22
1362	Different patterns of treatmentâ€related adverse events of programmed cell deathâ€1 and its ligandâ€1 inhibitors in different cancer types: A metaâ€analysis and systemic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e160-e178.	0.7	6
1363	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	3.8	15
1364	Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?. International Journal of Molecular Sciences, 2020, 21, 7935.	1.8	17
1365	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Frontiers in Immunology, 2020, 11, 2023.	2.2	50
1366	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Journal of Immunotherapy, 2020, 43, 291-298.	1.2	7
1367	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomarker Research, 2020, 8, 35.	2.8	122

#	Article	IF	Citations
1368	PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nature Communications, 2020, 11, 4835.	5.8	290
1369	Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Molecular Cancer Therapeutics, 2020, 19, 2105-2116.	1.9	10
1370	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nature Cell Biology, 2020, 22, 1264-1275.	4.6	508
1371	Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. Acta OncolÃ³gica, 2020, 59, 1447-1454.	0.8	18
1372	Using Gene Editing Approaches to Fine-Tune the Immune System. Frontiers in Immunology, 2020, 11, 570672.	2.2	13
1373	Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. , 2020, 8, e000873.		49
1374	CD8+ T Cell Co-Expressed Genes Correlate With Clinical Phenotype and Microenvironments of Urothelial Cancer. Frontiers in Oncology, 2020, 10, 553399.	1.3	26
1375	The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. Journal of Experimental and Clinical Cancer Research, 2020, 39, 284.	3.5	67
1376	Thymosin Î²10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. Respiratory Research, 2020, 21, 328.	1.4	18
1377	TGFÎ²-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. Nature Communications, 2020, 11, 6315.	5.8	106
1378	Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. , 2020, 8, e001673.		5
1379	iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and antiâ€“PD-1 therapy. Science Translational Medicine, 2020, 12, .	5.8	133
1380	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Science Advances, 2020, 6, eaay6298.	4.7	41
1381	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clinical Cancer Research, 2020, 26, 1141-1151.	3.2	43
1382	Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 687-696.	1.4	20
1383	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. British Journal of Cancer, 2020, 123, 92-100.	2.9	10
1384	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine, 2020, 26, 693-698.	15.2	250
1385	Blocking interaction between SHP2 and PDâ€1 denotes a novel opportunity for developing PDâ€1 inhibitors. EMBO Molecular Medicine, 2020, 12, e11571.	3.3	40

#	Article	IF	Citations
1386	Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives. Cancers, 2020, 12, 1181.	1.7	69
1387	A Pan-cancer Clinical Study of Personalized Neoantigen Vaccine Monotherapy in Treating Patients with Various Types of Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 4511-4520.	3.2	56
1388	Human cancer germline antigen-specific cytotoxic T cellâ€"what can we learn from patient. Cellular and Molecular Immunology, 2020, 17, 684-692.	4.8	12
1389	Antiâ€"PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infectionâ€"Related Advanced Hepatocellular Carcinoma: A Literature Review. Frontiers in Immunology, 2020, 11, 1037.	2.2	55
1390	PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nature Cancer, 2020, 1, 681-691.	5.7	240
1391	Circulating immune cell phenotype dynamics reflect the strength of tumorâ€"immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16072-16082.	3.3	60
1392	Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell, 2020, 181, 1612-1625.e13.	13.5	436
1393	Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer. Theranostics, 2020, 10, 7002-7014.	4.6	108
1394	ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Science Translational Medicine, 2020, 12, .	5.8	82
1395	Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Scientific Reports, 2020, 10, 9705.	1.6	57
1396	Nanomaterials for oncotherapies targeting the hallmarks of cancer. Nanotechnology, 2020, 31, 392001.	1.3	11
1397	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. Frontiers in Oncology, 2020, 10, 886.	1.3	4
1398	Regulation of Cancer Immune Checkpoints. Advances in Experimental Medicine and Biology, 2020, , .	0.8	7
1399	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Science Translational Medicine, 2020, 12, .	5.8	229
1400	Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma . International Journal of Nanomedicine, 2020, Volume 15, 1677-1691.	3.3	46
1401	Role of tumor microenvironment in the regulation of PDâ€L1: A novel role in resistance to cancer immunotherapy. Journal of Cellular Physiology, 2020, 235, 6496-6506.	2.0	19
1402	Computational Prediction and Validation of Tumor-Associated Neoantigens. Frontiers in Immunology, 2020, 11, 27.	2.2	86
1403	Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. Frontiers in Immunology, 2020, 11, 125.	2.2	53

#	Article	IF	Citations
1404	Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Letters, 2020, 478, 56-69.	3.2	32
1405	Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve. Bulletin Du Cancer, 2020, 107, eS1-eS7.	0.6	4
1406	PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity. Cellular and Molecular Immunology, 2021, 18, 2402-2409.	4.8	23
1407	LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. OncoImmunology, 2020, 9, 1736792.	2.1	36
1408	Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma. , 2020, 8, e000419.		7
1409	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Seminars in Cancer Biology, 2022, 79, 18-43.	4.3	35
1410	Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Research, 2020, 22, 69.	2.2	45
1411	Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 455-463.e4.	1.1	13
1412	The Immunoglobulin Superfamily Receptome Defines Cancer-Relevant Networks Associated with Clinical Outcome. Cell, 2020, 182, 329-344.e19.	13.5	66
1413	Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. Disease Markers, 2020, 2020, 1-16.	0.6	11
1414	The impact of PD-L1â€‰N-linked glycosylation on cancer therapy and clinical diagnosis. Journal of Biomedical Science, 2020, 27, 77.	2.6	89
1415	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57.	4.3	104
1416	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. European Journal of Cancer, 2020, 128, 119-128.	1.3	50
1417	PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 269-277.	1.4	13
1418	The emerging role of precision medicine in the treatment of endometrial cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 87-93.	0.4	1
1419	Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial. Contemporary Clinical Trials Communications, 2020, 17, 100536.	0.5	13
1420	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. Gastroenterology Report, 2020, 8, 11-24.	0.6	68
1421	VISTA: Coming of age as a multi-lineage immune checkpoint. Clinical and Experimental Immunology, 2020, 200, 120-130.	1.1	66

#	Article	IF	Citations
1422	Cytokines as potential combination agents with PDâ€1/PDâ€L1 blockade for cancer treatment. Journal of Cellular Physiology, 2020, 235, 5449-5460.	2.0	42
1423	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic Cancer, 2020, 11, 805-809.	0.8	8
1424	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. Cancers, 2020, 12, 230.	1.7	9
1425	Radiological Monitoring of Modern Immunotherapy: AÂNovelÂChallenge for Interdisciplinary Patient Care. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 235-245.	0.7	7
1426	The top 100 most cited manuscripts in bladder cancer: A bibliometric analysis (review article). International Journal of Surgery, 2020, 75, 130-138.	1.1	37
1427	Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-Î³-signaling mutant cancer cells. Nature Communications, 2020, 11, 602.	5.8	81
1428	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer, 2020, 18, 351-360.e3.	0.9	14
1429	Optimal PD-L1â€“high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE, 2020, 15, e0231936.	1.1	16
1431	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand) Tj ETQq0 0 0 rgBT /Overlock	1.6	10
1432	Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer. Journal of Cancer, 2020, 11, 2864-2873.	1.2	15
1433	Atezolizumab for the treatment of renal cell carcinoma. Expert Opinion on Biological Therapy, 2020, 20, 679-686.	1.4	0
1434	A Case of Isolated Adrenocorticotropic Hormone Deficiency Caused by Pembrolizumab. Case Reports in Oncology, 2020, 13, 200-206.	0.3	15
1435	Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters. Chinese Clinical Oncology, 2020, 9, 19-19.	0.4	6
1436	Microenvironmental Determinants of Pancreatic Cancer. Physiological Reviews, 2020, 100, 1707-1751.	13.1	156
1437	SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data. International Immunopharmacology, 2020, 84, 106490.	1.7	35
1438	Emerging treatments in advanced urothelial cancer. Current Opinion in Oncology, 2020, 32, 232-239.	1.1	2
1439	Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. , 2020, 8, e000205.		26
1440	An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer. Molecular Cancer Therapeutics, 2020, 19, 1373-1382.	1.9	20

#	Article	IF	Citations
1441	Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. Journal of Oncology Pharmacy Practice, 2020, 26, 1791-1794.	0.5	10
1442	Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 2378.	1.8	48
1443	Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study. Journal of Clinical Pathology, 2021, 74, 53-57.	1.0	15
1444	Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunology, Immunotherapy, 2021, 70, 1-18.	2.0	79
1445	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. Clinical and Translational Oncology, 2021, 23, 434-449.	1.2	6
1446	PD-L1 testing in urothelial bladder cancer: essentials of clinical practice. World Journal of Urology, 2021, 39, 1345-1355.	1.2	13
1447	PDâ€L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced nonâ€small cell lung cancer?. Journal of Gene Medicine, 2021, 23, e3294.	1.4	14
1448	Biomarkers for predicting the outcome of various cancer immunotherapies. Critical Reviews in Oncology/Hematology, 2021, 157, 103161.	2.0	10
1449	NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metabolism, 2021, 33, 110-127.e5.	7.2	137
1450	Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy, 2021, 70, 221-232.	2.0	12
1451	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood, 2021, 137, 216-231.	0.6	40
1452	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. Blood, 2021, 137, 1777-1791.	0.6	25
1453	Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. World Journal of Urology, 2021, 39, 1319-1329.	1.2	30
1454	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54.	4.4	31
1455	State-of-the-art advances of copper-based nanostructures in the enhancement of chemodynamic therapy. Journal of Materials Chemistry B, 2021, 9, 250-266.	2.9	92
1456	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	2.0	26
1457	PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies. Trends in Molecular Medicine, 2021, 27, 207-219.	3.5	23
1458	The impact of pre-analytical parameters on class II biomarkers by immunohistochemistry: concordance across four tissue processing protocols. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 985-993.	1.4	2

#	Article	IF	Citations
1459	Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy. Bioorganic and Medicinal Chemistry, 2021, 30, 115951.	1.4	7
1460	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Molecular Cancer Research, 2021, 19, 395-402.	1.5	7
1461	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 580045.	1.3	2
1462	Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy. Cancer Immunology, Immunotherapy, 2021, 70, 1177-1188.	2.0	60
1463	PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 195.e15-195.e23.	0.8	6
1464	Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitorâ€associated colitis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1180-1186.	1.4	1
1465	Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy, 2021, 70, 569-588.	2.0	14
1466	Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies. Clinical and Translational Oncology, 2021, 23, 882-891.	1.2	5
1467	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. Cellular and Molecular Life Sciences, 2021, 78, 867-887.	2.4	9
1468	Virus-stimulated neutrophils in the tumor microenvironment enhance T cell-mediated anti-tumor immunity. Oncotarget, 0, 7, 42195-42207.	0.8	26
1469	The synergistic antitumor activity of 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) and anti-PD-L1 antibody inducing immunogenic cell death. Drug Delivery, 2021, 28, 800-813.	2.5	7
1470	Identification of key genes and microRNA regulatory network in development and progression of urothelial bladder carcinoma. Translational Andrology and Urology, 2021, 10, 438-447.	0.6	1
1471	Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. Frontiers in Immunology, 2020, 11, 604967.	2.2	12
1472	A snapshot of the PD-1/PD-L1 pathway. Journal of Cancer, 2021, 12, 2735-2746.	1.2	105
1473	Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy. ACS Nano, 2021, 15, 515-525.	7.3	86
1474	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. Journal of Clinical and Translational Research, 0, , .	0.3	10
1475	Emerging role of circulating tumor cells in immunotherapy. Theranostics, 2021, 11, 8057-8075.	4.6	19
1476	Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy. Theranostics, 2021, 11, 6033-6043.	4.6	22

#	Article	IF	Citations
1477	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
1478	Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer. Journal of Cancer, 2021, 12, 2000-2009.	1.2	1
1479	Immunotherapy for Metastatic Urothelial Carcinoma. , 2021, , 305-313.		0
1480	Industrial Perspective on Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1295, 327-347.	0.8	0
1481	Medical Treatment with Targeted Therapy for Metastatic Urothelial Bladder Carcinoma. , 2021, , 199-209.		1
1482	PD-LI Promotes Retraction Fiber Formation and Determines Persistent Cell Migration by Altering Integrin Î²4 Dynamics. SSRN Electronic Journal, 0, , .	0.4	0
1484	A 4 Gene-based Immune Signature Predicts Dedifferentiation and Immune Exhaustion in Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3208-e3220.	1.8	5
1485	STAT1 is a key gene in a gene regulatory network related to immune phenotypes in bladder cancer: An integrative analysis of multiâ€omics data. Journal of Cellular and Molecular Medicine, 2021, 25, 3258-3271.	1.6	3
1486	Tislelizumab uniquely binds to the CCâ€² loop of PDâ€1 with slowâ€dissociated rate and complete PDâ€L1 blockage. FEBS Open Bio, 2021, 11, 782-792.	1.0	32
1487	PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. Current Drug Targets, 2021, 22, 162-170.	1.0	16
1488	Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study. OncoTargets and Therapy, 2021, Volume 14, 845-855.	1.0	5
1489	Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumors. PLoS ONE, 2021, 16, e0246048.	1.1	0
1490	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology, 2021, 18, 345-362.	12.5	646
1491	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 1524-1541.	7.7	103
1492	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. Cancers, 2021, 13, 729.	1.7	3
1493	Neural stem cells secreting bispecific T cell engager to induce selective antiglioma activity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	18
1494	Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry. Scientific Reports, 2021, 11, 4165.	1.6	3
1495	Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathology Research and Practice, 2021, 218, 153322.	1.0	51

#	Article	IF	Citations
1496	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung Journal of Medical Sciences, 2021, 37, 448-458.	0.8	15
1497	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. Frontiers in Immunology, 2021, 12, 630773.	2.2	22
1498	Phenotypic and Functional Analyses Guiding Combination Immune Checkpoint Immunotherapeutic Strategies in HTLV-1 Infection. Frontiers in Immunology, 2021, 12, 608890.	2.2	8
1499	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Annals of Translational Medicine, 2021, 9, 423-423.	0.7	6
1500	Immunotherapy and predictive immunologic profile: the tip of the iceberg. Medical Oncology, 2021, 38, 51.	1.2	4
1501	The Roles of T cells in Bladder Pathologies. Trends in Immunology, 2021, 42, 248-260.	2.9	12
1502	CCL5 production by fibroblasts through a local reninâ€“angiotensin system in malignant melanoma affects tumor immune responses. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1993-2001.	1.2	9
1503	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. Cancers, 2021, 13, 1424.	1.7	21
1504	Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646982.	1.8	7
1505	Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumorâ€“Immune Interactions. International Journal of Molecular Sciences, 2021, 22, 3374.	1.8	9
1507	Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer. Annals of Nuclear Medicine, 2021, 35, 415-420.	1.2	3
1508	Coming of Age of Immunotherapy of Urothelial Cancer. Targeted Oncology, 2021, 16, 283-294.	1.7	2
1509	Unraveling the Role of Immune Checkpoints in Leishmaniasis. Frontiers in Immunology, 2021, 12, 620144.	2.2	18
1510	Peptideâ€based therapeutic cancer vaccine: Current trends in clinical application. Cell Proliferation, 2021, 54, e13025.	2.4	68
1511	M2 Macrophage Co-Expression Factors Correlate With Immune Phenotype and Predict Prognosis of Bladder Cancer. Frontiers in Oncology, 2021, 11, 609334.	1.3	19
1512	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 1402.	5.8	85
1513	Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 596484.	1.8	7
1514	Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 546586.	1.3	30

#	Article	IF	Citations
1515	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 617335.	1.3	49
1516	PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients withÂbreast cancer: TNBC versus TPBC. Breast Disease, 2021, 40, 43-50.	0.4	11
1517	Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy. Frontiers in Immunology, 2021, 12, 679117.	2.2	22
1518	Time-dependent population PK models of single-agent atezolizumab in patients with cancer. Cancer Chemotherapy and Pharmacology, 2021, 88, 211-221.	1.1	13
1519	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer, 2021, 21, 425.	1.1	16
1520	Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy. Cancers, 2021, 13, 1863.	1.7	6
1521	Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. Frontiers in Molecular Biosciences, 2021, 8, 607090.	1.6	12
1522	CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. Cancer Immunology, Immunotherapy, 2021, 70, 3235-3248.	2.0	23
1523	FOXO3A Expression in Upper Tract Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 603681.	1.3	4
1524	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Journal of Pancreatic Cancer, 2021, 7, 31-38.	1.6	2
1525	Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment. Cancer Letters, 2021, 503, 151-162.	3.2	1
1526	PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity. Genome Biology, 2021, 22, 104.	3.8	42
1529	Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. , 2021, 9, e002171.		12
1530	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology, 2021, 23, 2237-2252.	1.2	7
1531	Radiomic biomarkers of tumor immune biology and immunotherapy response. Clinical and Translational Radiation Oncology, 2021, 28, 97-115.	0.9	22
1532	Atlantis exploration: predictive biomarkers to immunotherapy response. Onkourologiya, 2021, 17, 167-177.	0.1	1
1533	PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. Minerva Respiratory Medicine, 2021, 60, .	0.1	4
1534	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. Journal of Experimental Medicine, 2021, 218, .	4.2	53

#	Article	IF	Citations
1535	Genome profiling of mismatch repair genes in eight types of tumors. Cell Cycle, 2021, 20, 1-16.	1.3	0
1536	Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation. Frontiers in Oncology, 2021, 11, 643413.	1.3	3
1537	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. International Journal of Molecular Sciences, 2021, 22, 6741.	1.8	28
1538	Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer. Bioscience Reports, 2021, 41, .	1.1	12
1539	Current Therapy for Metastatic Urothelial Carcinoma. Hematology/Oncology Clinics of North America, 2021, 35, 469-493.	0.9	4
1540	Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy. Urology, 2021, 157, 93-101.	0.5	6
1541	Evaluating the impacts of emerging cancer therapies on ovarian function. Current Opinion in Endocrine and Metabolic Research, 2021, 18, 15-28.	0.6	6
1542	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Annals of Allergy, Asthma and Immunology, 2021, 126, 630-638.	0.5	23
1543	Molecular Classification of Bladder Cancer. , 0, , .		0
1544	Detrimental Effect of Various Preparations of the Human Amniotic Membrane Homogenate on the 2D and 3D Bladder Cancer In vitro Models. Frontiers in Bioengineering and Biotechnology, 2021, 9, 690358.	2.0	6
1545	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
1546	Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer. Journal of Oncology, 2021, 2021, 1-20.	0.6	3
1547	Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma. Translational Andrology and Urology, 2021, 10, 2929-2937.	0.6	5
1548	DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma. Frontiers in Immunology, 2021, 12, 676922.	2.2	15
1549	miRâ€148aâ€3p silences the CANX/MHCâ€I pathway and impairs CD8⁺T cellâ€mediated immune attack in colorectal cancer. FASEB Journal, 2021, 35, e21776.	0.2	24
1550	Immunotherapy: New insights in breast cancer treatment. Human Antibodies, 2021, 29, 193-202.	0.6	3
1551	Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperative tumor recurrence. Acta Pharmaceutica Sinica B, 2021, 11, 1978-1992.	5.7	14
1552	The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Frontiers in Immunology, 2021, 12, 638763.	2.2	23

#	Article	IF	Citations
1553	Pyroptosis, a New Breakthrough in Cancer Treatment. Frontiers in Oncology, 2021, 11, 698811.	1.3	29
1554	High-affinity decoy PD-1 mutant screened from an epitope-specific cell library. Engineering, 2021, , .	3.2	1
1555	Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clinical Genitourinary Cancer, 2022, 20, e16-e24.	0.9	1
1556	Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 110, 738-741.	0.4	27
1557	The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ TÂcell dysfunction and tumor growth. Cancer Cell, 2021, 39, 945-957.e10.	7.7	124
1558	Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Molecular Therapy, 2022, 30, 662-671.	3.7	25
1559	Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer. Frontiers in Immunology, 2021, 12, 724541.	2.2	3
1560	The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models. Cancer Management and Research, 2021, Volume 13, 6045-6053.	0.9	8
1561	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. World Journal of Gastroenterology, 2021, 27, 5362-5375.	1.4	17
1562	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitorâ€"Related Esophagitis. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 896-904.	2.3	13
1563	Outcomes in primary cutaneous diffuse large Bâ€cell lymphoma, leg type. Hematological Oncology, 2021, 39, 658-663.	0.8	8
1564	Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer. Frontiers in Genetics, 2021, 12, 696912.	1.1	5
1566	The efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating advanced urothelial cancer: a meta-analysis of clinical trials. Aging, 2021, 13, 20468-20480.	1.4	3
1567	Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in â€œHigh-Riskâ€• Patients Following Radical Cystectomy: A Retrospective Cohort Study. Frontiers in Oncology, 2021, 11, 706503.	1.3	2
1568	Current status and future perspectives of immunotherapy against urothelial and kidney cancer. Japanese Journal of Clinical Oncology, 2021, 51, 1481-1492.	0.6	7
1569	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. Expert Review of Anticancer Therapy, 2021, 21, 1211-1228.	1.1	1
1571	24th â€œNantes ActualitÃ©s en Transplantationâ€•and 4th â€œLabEx Immunotherapy-Graft-Oncologyâ€•NAT and IGO Joint Meeting â€œNew Horizons in Immunotherapyâ€• Frontiers in Immunology, 2021, 12, 738312.	2.2	0
1572	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers, 2021, 13, 4712.	1.7	29

#	Article	IF	Citations
1573	Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World Journal of Urology, 2022, 40, 915-927.	1.2	8
1574	CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene, 2021, 40, 6223-6234.	2.6	42
1575	A fatal affair: Circulating tumor cell relationships that shape metastasis. IScience, 2021, 24, 103073.	1.9	8
1576	Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. Frontiers in Cell and Developmental Biology, 2021, 9, 717601.	1.8	6
1577	Clinical therapies and nano drug delivery systems for urinary bladder cancer. , 2021, 226, 107871.		42
1578	Immune checkpoints and reproductive immunology: Pioneers in the future therapy of infertility related Disorders?. International Immunopharmacology, 2021, 99, 107935.	1.7	19
1579	Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorganic Chemistry, 2021, 116, 105366.	2.0	11
1580	Hypoxia and the phenomenon of immune exclusion. Journal of Translational Medicine, 2021, 19, 9.	1.8	63
1581	CircRNA-100284 activates aurora kinase B by inducing methylation of HSP70 via microRNA-217 to promote proliferation of bladder cancer cells. Journal of Cancer Research and Clinical Oncology, 2021, 147, 703-712.	1.2	8
1582	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers, 2021, 13, 373.	1.7	18
1583	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110449.	0.6	18
1584	A mathematical model for the quantification of a patientâ€™s sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 2021, 5, 297-308.	11.6	28
1585	Role of immunotherapy in bladder cancer. Cancer Treatment and Research Communications, 2021, 26, 100296.	0.7	41
1586	Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer. OncoImmunology, 2021, 10, 1915574.	2.1	21
1587	Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer. Polymers, 2021, 13, 341.	2.0	27
1588	Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity. Communications Biology, 2021, 4, 78.	2.0	10
1589	Overview of Tissue Imaging Methods. Methods in Molecular Biology, 2020, 2055, 455-465.	0.4	23
1590	Current Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 107-147.	0.8	3

#	Article	IF	Citations
1591	Preclinical Applications of Magnetic Resonance Imaging in Oncology. Recent Results in Cancer Research, 2020, 216, 405-437.	1.8	1
1592	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. Advances in Experimental Medicine and Biology, 2020, 1257, 109-131.	0.8	7
1593	Therapeutic Development of Immune Checkpoint Inhibitors. Advances in Experimental Medicine and Biology, 2020, 1248, 619-649.	0.8	15
1594	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Advances in Experimental Medicine and Biology, 2020, 1248, 33-59.	0.8	232
1595	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Advances in Experimental Medicine and Biology, 2020, 1248, 143-166.	0.8	3
1596	The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clinical Genitourinary Cancer, 2018, 16, e269-e276.	0.9	39
1597	PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology, 2020, 152, 102973.	2.0	31
1598	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€“Selected Advanced Nonâ€“Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	0.8	24
1599	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer, 2018, 119, 80-88.	2.9	74
1600	Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Communications Biology, 2020, 3, 784.	2.0	21
1601	p110Î´ PI3K as a therapeutic target of solid tumours. Clinical Science, 2020, 134, 1377-1397.	1.8	15
1602	PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. Journal of Cell Biology, 2020, 219, .	2.3	65
1603	PD-L1 Expression in Extramammary Paget Disease: A Case Series. American Journal of Dermatopathology, 2021, 43, 21-26.	0.3	2
1604	Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. Journal of Urology, 2019, 202, 49-56.	0.2	24
1605	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. Journal of Urology, 2020, 204, 1173-1179.	0.2	47
1606	Clinical Significance of Program Death Ligand-1 and Indoleamine-2,3-Dioxygenase Expression in Colorectal Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2020, Publish Ahead of Print, 201-208.	0.6	6
1607	Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. International Journal of Gynecological Pathology, 2021, 40, 148-155.	0.9	7
1608	The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead. Open Biology, 2020, 10, 200188.	1.5	27

#	Article	IF	Citations
1614	Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Science, 2021, 112, 760-773.	1.7	49
1615	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. International Journal of Dermatology, 2019, 58, 1045-1052.	0.5	11
1617	Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma. Journal of Immunology Research, 2020, 2020, 1-15.	0.9	11
1618	Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK. JCI Insight, 2019, 4, .	2.3	40
1619	Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3â€“CD8+ T cells. JCI Insight, 2020, 5, .	2.3	30
1620	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight, 2016, 1, e85902.	2.3	179
1621	Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight, 2016, 1, e88955.	2.3	111
1622	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation, 2019, 129, 616-630.	3.9	94
1623	Pembrolizumab plus allogeneic NK cells in advanced nonâ€“small cell lung cancer patients. Journal of Clinical Investigation, 2020, 130, 2560-2569.	3.9	77
1624	ILC2-modulated T cellâ€“to-MDSC balance is associated with bladder cancer recurrence. Journal of Clinical Investigation, 2017, 127, 2916-2929.	3.9	176
1625	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockadeâ€“mediated tumor regression. Journal of Clinical Investigation, 2018, 128, 805-815.	3.9	423
1626	Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Journal of Clinical Investigation, 2019, 129, 1278-1294.	3.9	102
1627	Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. Journal of Clinical Investigation, 2018, 128, 4654-4668.	3.9	591
1628	A Case Report of Atezolizumab Induced Tumor Lysis Syndrome. American Journal of Case Reports, 2019, 20, 785-789.	0.3	9
1629	Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer. Medical Science Monitor, 2018, 24, 7303-7308.	0.5	5
1630	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	0.8	5
1631	Cancer Genomics. F1000Research, 2015, 4, 1162.	0.8	2
1632	Immunotherapyâ€Induced Colitis: An Emerging Problem for the Hospitalist. Journal of Hospital Medicine, 2018, 13, 413-418.	0.7	25

#	Article	IF	Citations
1633	PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS ONE, 2015, 10, e0131403.	1.1	288
1634	The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types. PLoS ONE, 2015, 10, e0138726.	1.1	24
1635	The prognostic significance of DAPK1 in bladder cancer. PLoS ONE, 2017, 12, e0175290.	1.1	17
1636	Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis. PLoS ONE, 2017, 12, e0176822.	1.1	64
1637	TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens, 2016, 12, e1005349.	2.1	271
1638	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	1.8	12
1639	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocrine-Related Cancer, 2019, 26, R157-R179.	1.6	34
1640	Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia. Endocrine-Related Cancer, 2019, 26, 293-301.	1.6	62
1641	The overview of modern approaches in treatment of triple negative breast cancer. IssledovaniÃ¢ I Praktika V Medicine, 2020, 7, 55-65.	0.1	1
1642	Establishment of a novel risk score model by comprehensively analyzing the immunogen database of bladder cancer to indicate clinical significance and predict prognosis. Aging, 2020, 12, 11967-11989.	1.4	11
1643	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget, 2016, 7, 64967-64976.	0.8	42
1644	Foxp3 enhances HIF-1Î± target gene expression in human bladder cancer through decreasing its ubiquitin-proteasomal degradation. Oncotarget, 2016, 7, 65403-65417.	0.8	12
1645	Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget, 2016, 7, 71198-71210.	0.8	81
1646	T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget, 2016, 7, 76902-76919.	0.8	131
1647	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget, 2017, 8, 8807-8817.	0.8	68
1648	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 80164-80174.	0.8	40
1649	Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer. Oncotarget, 2017, 8, 9354-9365.	0.8	32
1650	The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer. Oncotarget, 2017, 8, 15584-15592.	0.8	101

#	Article	IF	Citations
1651	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget, 2017, 8, 14416-14427.	0.8	70
1652	Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget, 2017, 8, 28176-28186.	0.8	42
1653	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 30175-30189.	0.8	69
1654	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget, 2017, 8, 20558-20571.	0.8	49
1655	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
1656	Sequencing of cancer cell subpopulations identifies micrometastases in a bladder cancer patient. Oncotarget, 2017, 8, 45619-45625.	0.8	8
1657	Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. Oncotarget, 2017, 8, 44326-44334.	0.8	19
1658	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget, 2017, 8, 54722-54734.	0.8	39
1659	Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. Oncotarget, 2017, 8, 57889-57897.	0.8	26
1660	SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget, 2017, 8, 53518-53530.	0.8	33
1661	Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. Oncotarget, 2017, 8, 76656-76665.	0.8	39
1662	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. Oncotarget, 2018, 9, 10284-10293.	0.8	44
1663	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget, 2018, 9, 5652-5664.	0.8	105
1664	Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Oncotarget, 2018, 9, 13920-13933.	0.8	60
1665	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget, 2018, 9, 28702-28716.	0.8	27
1666	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNFÎ± mediated immune responses in a model of NSCLC. Oncotarget, 2018, 9, 37157-37172.	0.8	10
1667	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget, 2015, 6, 19393-19404.	0.8	61
1668	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499.	0.8	212

#	Article	IF	Citations
1669	CD274/PD-L1gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget, 2016, 7, 12024-12034.	0.8	141
1670	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget, 2016, 7, 33350-33362.	0.8	56
1671	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. Oncotarget, 2016, 7, 52442-52449.	0.8	6
1672	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	1.4	95
1673	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	0.7	9
1674	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	0.7	17
1675	Immunobiology and immunotherapy in genitourinary malignancies. Annals of Translational Medicine, 2016, 4, 270-270.	0.7	14
1676	Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas. Annals of Translational Medicine, 2019, 7, 387-387.	0.7	13
1677	PD-L1 assessment in urothelial carcinoma: a practical approach. Annals of Translational Medicine, 2019, 7, 690-690.	0.7	77
1678	CLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCER. Siberian Journal of Oncology, 2020, 18, 140-144.	0.1	1
1679	Cancer Biomarker Discovery for Precision Medicine: New Progress. Current Medicinal Chemistry, 2020, 26, 7655-7671.	1.2	51
1680	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry, 2020, 27, 2402-2448.	1.2	12
1681	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets, 2015, 15, 652-664.	0.8	33
1682	Immune Blockade Inhibition in Breast Cancer. Anticancer Research, 2016, 36, 5607-5622.	0.5	37
1683	The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma. Anticancer Research, 2017, 37, 2159-2171.	0.5	57
1684	Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, 37, 5713-5717.		24
1685	Epidemiology and unmet needs of bladder cancer in Italy: a critical review. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 1-12.	3.9	13
1686	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. International Journal of Molecular Sciences, 2020, 21, 7139.	1.8	33

#	Article	IF	Citations
1687	Perspectives in the treatment of pancreatic adenocarcinoma. World Journal of Gastroenterology, 2015, 21, 9297.	1.4	124
1688	Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World Journal of Gastroenterology, 2020, 26, 353-365.	1.4	54
1689	Atezolizumab alleviates the immunosuppressionÂinduced by PDâ€'L1â€'positive neutrophils and improves the survival of mice during sepsis. Molecular Medicine Reports, 2020, 23, .	1.1	14
1690	Mechanistic insight of predictive biomarkers for antitumor PDâ€'1/PDâ€'L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncology Reports, 2020, 44, 424-437.	1.2	18
1691	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Translational Lung Cancer Research, 2015, 4, 743-51.	1.3	31
1692	Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Translational Andrology and Urology, 2015, 4, 273-82.	0.6	4
1693	Intravesical immunotherapy in nonmuscle invasive bladder cancer. Indian Journal of Urology, 2015, 31, 304.	0.2	10
1694	Systemic therapy in bladder cancer. Indian Journal of Urology, 2017, 33, 118.	0.2	9
1695	New therapies in nonmuscle invasive bladder cancer treatment. Indian Journal of Urology, 2018, 34, 11.	0.2	35
1696	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Translational Oncogenomics, 2015, Suppl. 1, 1-11.	1.7	19
1697	Dynamic Duo: Synergy between Cancer Radiation Therapy and Immunotherapy. Immunotherapy (Los) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	1
1698	Overview of Research and Development for Anticancer Drugs. Journal of Cancer Therapy, 2016, 07, 762-772.	0.1	21
1699	Anti program death-1/anti program death-ligand 1 in digestive cancers. World Journal of Gastrointestinal Oncology, 2015, 7, 95.	0.8	53
1700	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	0.9	52
1701	Cancer immunotherapy by targeting immune checkpoint receptors. World Journal of Immunology, 2018, 8, 1-11.	0.5	4
1702	Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biology and Medicine, 2015, 12, 87-95.	1.4	35
1703	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biology and Medicine, 2015, 12, 201-8.	1.4	67
1704	Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. ELife, 2019, 8, .	2.8	19

#	Article	IF	Citations
1705	Multiomics analysis of tumor mutational burden across cancer types. Computational and Structural Biotechnology Journal, 2021, 19, 5637-5646.	1.9	10
1706	Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110229.	1.4	3
1707	The New Frontier in Medicine at the Convergence of Nanotechnology and Immunotherapy. Bioanalysis, 2021, , 3-27.	0.1	0
1708	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	5.8	33
1709	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. Archives of Dermatological Research, 2021, , 1.	1.1	3
1710	Exploring microsatellite instability in patients with advanced hepatocellular carcinoma and its tumor microenvironment. JGH Open, 2021, 5, 1266-1274.	0.7	9
1711	Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis. Journal of Clinical Investigation, 2021, 131, .	3.9	5
1712	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
1713	Sweet side of bladder cancer. World Journal of Clinical Urology, 2015, 4, 104.	0.0	0
1714	Muscle-invasive transitional cell carcinoma of the bladder. , 2015, , 133-142.		0
1715	Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, .	11.0	0
1716	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
1717	Promising Immunotherapeutic Approaches in Clinical Trials. , 2016, , 351-416.		1
1718	Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16.	0.1	0
1719	Systemic treatment for bladder cancer. Urologie Pro Praxi, 2016, 17, 102-105.	0.0	1
1721	Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. , 2017, , 31-44.		0
1723	Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. , 2017, , 201-237.		0
1724	Targeted Therapies and ImmunotherapyImmunotherapy in bladder cancer in Bladder Cancer. , 2017, , 111-122.		0

#	Article	IF	Citations
1725	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0
1726	Personalized Peptide Vaccine for Advanced Pancreatic Cancer. , 2017, , 445-451.		0
1727	Systemic Therapy for Bladder Cancer. , 2017, , 103-109.		0
1728	Use of Atezolizumab for Bladder and Nonâ€“Small Cell Lung Cancers. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	0
1729	Maintenance treatment with gemcitabine have a promising activity on metastatic bladder cancer survival. Turkish Journal of Urology, 2017, 43, 273-278.	1.3	3
1730	Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235.	0.5	0
1731	Metastatic Bladder Cancer Disease and Its Treatment. , 2018, , 1-9.		0
1732	Immunotherapy in urothelial cancer: recent data and perspectives. Onkourologiya, 2018, 13, 16-24.	0.1	2
1733	Dynamic changes in PD-1 and PD-L1 expressions in cases with Hodgkin Lymphoma. Clinical Research and Trials, 2018, 4, .	0.1	1
1734	Voluntary Wheel Running Regulates Tumor Immunogenicity and Response to Immune Checkpoint Therapy. SSRN Electronic Journal, 0, , .	0.4	0
1735	Immunotherapy and New Combinations in Muscle-Invasive Bladder Cancer. , 2018, , 91-98.		0
1736	What about Treatment of Metastatic Bladder Cancer. Chemotherapy, 2018, 07, .	0.0	0
1737	Adjuvant Treatment: Old and New Immunotherapy in Non-Muscle-Invasive Bladder Cancer. , 2018, , 43-47.		0
1738	ULTRASOUND TUMOR ABLATION: IMMUNE EFFECTS AND PERSPECTIVES OF INTEGRATION IN THE MODERN TREATMENT OF ADVANCED CANCER. Malignant Tumours, 2018, 8, 31-42.	0.1	0
1739	Prise en charge du cancer du canal anal en 2018. Oncologie, 2018, 20, 94-106.	0.2	1
1740	In Vitro Cancer Diagnostics. Bioanalysis, 2019, , 109-132.	0.1	0
1741	T Cell Senescence and Tumor Immunotherapy. , 2019, , 2091-2114.		0
1742	Programmed Death-1 and Programmed Death Ligand-1 Blockade for Advanced Urothelial Carcinoma. Urological Science, 2019, 30, 2-7.	0.2	2

#	Article	IF	Citations
1744	Checkmate with Checkpoint Inhibitors: Hope and Hype. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 159-162.	0.1	0
1746	The Systematic Review of the Efficacy and Safety of Immune Checkpoint Inhibitor in Urological Cancers. The Korean Journal of Urological Oncology, 2019, 17, 75-80.	0.1	0
1747	Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. Onkourologiya, 2019, 15, 113-119.	0.1	0
1748	Immunotherapy in the Management of Colorectal Cancer Liver Metastasis. , 2020, , 269-282.		0
1749	The Role of TGF-Î² and PD-L1 in the Invasion and Development of Bladder Cancer. Advances in Clinical Medicine, 2020, 10, 1917-1925.	0.0	0
1750	Prognostic and predictive role of the tumor immune landscape. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 143-151.	0.4	3
1752	DERN CONTROL POINT INHIBITORS AND THEIR POSSIBILITIES FOR THE THERAPY OF METASTATIC UROTELIAL CANCER. EurasianUnionofScientists, 2020, 6, 4-8.	0.0	0
1753	Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis. Biochemical and Biophysical Research Communications, 2020, 527, 453-457.	1.0	10
1755	Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. , 2021, 9, e003036.		12
1756	EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals, 2021, 14, 1081.	1.7	37
1757	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Disease Markers, 2021, 2021, 1-10.	0.6	2
1758	Introduction on Cancer Immunology and Immunotherapy. , 2020, , 1-9.		0
1759	Prognostic value of programmed cell death ligand-1 expression in breast cancer. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	5
1760	Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-Î³ Signaling. Current Cancer Drug Targets, 2020, 20, 868-874.	0.8	5
1761	Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report. Annals of Translational Medicine, 2020, 8, 1609-1609.	0.7	4
1762	WGCNA and LASSO algorithm constructed an immune infiltration-related 5-gene signature and nomogram to improve prognosis prediction of hepatocellular carcinoma. Biocell, 2022, 46, 401-415.	0.4	5
1763	Identification of an Immune Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1764	Immunology in Tumor and Transplant. , 2020, , 175-184.		0

#	Article	IF	Citations
1765	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. Euroasian Journal of Hepato-gastroenterology, 2021, 10, 56-63.	0.1	5
1766	Targeting the Immune System in Pancreatic Cancer. Molecular and Translational Medicine, 2020, , 203-218.	0.4	0
1767	The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. Anticancer Research, 2020, 40, 1141-1146.	0.5	3
1770	Quinazoline Derivatives as Potential Therapeutic Agents in Urinary Bladder Cancer Therapy. Frontiers in Chemistry, 2021, 9, 765552.	1.8	21
1771	The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 2022, 81, 95-103.	0.9	158
1772	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. Angewandte Chemie - International Edition, 2021, 60, 26320-26326.	7.2	55
1773	Light-controlled elimination of PD-L1+ cells. Journal of Photochemistry and Photobiology B: Biology, 2021, 225, 112355.	1.7	5
1774	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. Angewandte Chemie, 2021, 133, 26524-26530.	1.6	2
1775	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. ELife, 2021, 10, .	2.8	8
1778	Palliative cystectomy. Is there a place in bladder cancer surgery?. Urology Herald, 2020, 8, 18-29.	0.1	0
1779	Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse. International Journal of Physiology, Pathophysiology and Pharmacology, 2015, 7, 87-97.	0.8	5
1780	Shedding light on the molecular determinants of response to anti-PD-1 therapy. Translational Lung Cancer Research, 2015, 4, 816-9.	1.3	18
1781	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology, 2015, 29, 331-40.	0.4	45
1782	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. American Journal of Translational Research (discontinued), 2016, 8, 3274-87.	0.0	35
1784	Use of Atezolizumab for Bladder and Non-Small Cell Lung Cancers. Journal of the Advanced Practitioner in Oncology, 2017, 8, 535-538.	0.2	0
1785	Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis. Indian Journal of Urology, 2019, 35, 101-115.	0.2	1
1786	Bladder Cancer Academy 2019 Selected Summaries. Reviews in Urology, 2019, 21, 23-28.	0.9	3
1788	Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors. International Journal of Clinical and Experimental Pathology, 2019, 12, 876-884.	0.5	0

#	Article	IF	Citations
1789	Rosiglitazone induces apoptosis on human bladder cancer 5637 and T24 cell lines. International Journal of Clinical and Experimental Pathology, 2017, 10, 10197-10204.	0.5	0
1790	The Role of Immunotherapy in Urologic Cancers. Missouri Medicine, 2020, 117, 127-132.	0.3	1
1792	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. Matter, 2019, 1, 1331-1353.	5.0	20
1793	CD204-positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligand-1 expression. Oncology Letters, 2021, 21, 36.	0.8	4
1794	Immune escape mechanisms and immunotherapy of urothelial bladder cancer. Journal of Clinical and Translational Research, 2021, 7, 485-500.	0.3	5
1795	Parameters of Tumor Microenvironment Determine Effectiveness of Anti-PD-1/PD-L1 Therapy. Biochemistry (Moscow), 2021, 86, 1461-1468.	0.7	2
1796	A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer. Frontiers in Immunology, 2021, 12, 724107.	2.2	17
1797	ÐŸÐ°Ñ€Ð°Ð¼ÐµÑ‚Ñ‹ Ð¼Ð¸ÐºÑ€Ð¾Ñ€ÐµÐ´Ð¾ÐºÑ€ÑƒÐ¶ÐµÐ½Ð¸Ñ•Ð¾Ð¿ÑƒÑ…Ð¾Ð»Ð¸ Ð¾Ð¿Ñ€ÐµÐ´ÐµÐ»ÑÑŽÑ‚ Ð±Ð¾Ð»ÐµÐµ Ð±Ð»Ð°Ð³Ð¾Ð¿Ñ€Ð¸ÑÑ‚Ð½Ñ‹Ð¹		
1798	A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer. Frontiers in Oncology, 2021, 11, 737323.	1.3	2
1799	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. Cell Communication and Signaling, 2021, 19, 117.	2.7	25
1800	Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduction and Targeted Therapy, 2021, 6, 398.	7.1	84
1801	Correlation between High PD-L1 and EMT/Invasive Genes Expression and Reduced Recurrence-Free Survival in Blood-Circulating Tumor Cells from Patients with Non-Muscle-Invasive Bladder Cancer. Cancers, 2021, 13, 5989.	1.7	11
1802	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers, 2021, 13, 5819.	1.7	4
1803	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Science Immunology, 2021, 6, eabc6424.	5.6	64
1804	Identification of Survival and Therapeutic Response-Related Ferroptosis Regulators in Bladder Cancer through Data Mining and Experimental Validation. Cancers, 2021, 13, 6069.	1.7	4
1805	Landscape of Immunotherapy in Genitourinary Malignancies. Advances in Experimental Medicine and Biology, 2021, 1342, 143-192.	0.8	2
1806	Immunological Significance of Alternative Splicing Prognostic Signatures for Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	0
1807	Polymeric PD-L1 blockade nanoparticles for cancer photothermal-immunotherapy. Biomaterials, 2022, 280, 121312.	5.7	28

#	Article	IF	Citations
1808	Avelumab in locally advanced or metastatic urothelial carcinoma. Expert Review of Anticancer Therapy, 2022, , .	1.1	1
1809	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. Expert Review of Anticancer Therapy, 2022, 22, 17-25.	1.1	7
1810	Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy. ESMO Open, 2022, 7, 100346.	2.0	5
1811	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology, 2022, 103, 108484.	1.7	2
1812	Inhibiting VEGF in cancer immunotherapy. Clinical Immunology Communications, 2022, 2, 12-16.	0.5	3
1813	CD204â€‘positive macrophages accumulate in breast cancer tumors with high levels of infiltrating lymphocytes and programmed death ligandâ€‘1 expression. Oncology Letters, 2020, 21, 1-1.	0.8	5
1814	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. International Journal of Pharmaceutics, 2022, 616, 121527.	2.6	16
1815	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	6.9	17
1816	High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Frontiers in Immunology, 2021, 12, 779248.	2.2	3
1817	Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer. Cancer Management and Research, 2022, Volume 14, 67-88.	0.9	1
1818	RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy. Clinical Oncology, 2022, 34, 421-425.	0.6	3
1819	Gene network profiling in muscle-invasive bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 197.e11-197.e23.	0.8	2
1820	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 832942.	2.2	18
1821	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing Î³Î´ T cells. Nature Communications, 2022, 13, 231.	5.8	14
1823	Identification of an IDO1â€based immune classifier for survival prediction of upper tract urothelial carcinoma. Cancer Science, 2021, , .	1.7	1
1824	The Pellino1â€“PKCÎ¸ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function. Cancer Immunology Research, 2022, 10, 327-342.	1.6	8
1825	Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents. Journal of Nanobiotechnology, 2022, 20, 64.	4.2	5
1826	Current Immunotherapeutic Approaches for Malignant Gliomas. Brain Tumor Research and Treatment, 2022, 10, 1.	0.4	5

#	Article	IF	Citations
1827	Prognostic value and underlying mechanism of autophagy-related genes in bladder cancer. Scientific Reports, 2022, 12, 2219.	1.6	3
1828	Inhibition of miR-1247 on cell proliferation and invasion in bladder cancer through its downstream target of RAB36. Journal of Biosciences, 2018, 43, 365-373.	0.5	7
1829	Grading of lymphocyte infiltrating tumor can be used as a prognosis factor compared to T Pathology and N Pathology on recurrency of colon cancer. Indonesia Journal of Biomedical Science, 2020, 15, 39-42.	0.1	0
1830	A Final Reflection of my Clinical Practice Journey. , 2022, , 209-217.		0
1831	Immune Contexture of Pediatric Cancers. SSRN Electronic Journal, 0, , .	0.4	0
1832	Biomarkers of response to PD-1 pathway blockade. British Journal of Cancer, 2022, 126, 1663-1675.	2.9	52
1833	Immunological significance of alternative splicing prognostic signatures for bladder cancer. Heliyon, 2022, 8, e08994.	1.4	1
1834	Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN-Î³ through PD-L1 and IDO1. Neuro-Oncology Advances, 2022, 4, .	0.4	8
1835	Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy. Frontiers in Cell and Developmental Biology, 2022, 10, 826879.	1.8	9
1836	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. International Journal of General Medicine, 2022, Volume 15, 2645-2667.	0.8	9
1837	PDL1 positivity rate between triple negative and non-luminal Her2+ cases. Current Cancer Therapy Reviews, 2022, 18, .	0.2	0
1838	Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, 801909.	2.2	4
1839	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. Journal of Clinical Oncology, 2022, 40, 2013-2022.	0.8	75
1840	Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively. Frontiers in Immunology, 2022, 13, 837512.	2.2	20
1841	Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics. Frontiers in Pharmacology, 2022, 13, 836925.	1.6	4
1842	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer. Frontiers in Immunology, 2022, 13, 827921.	2.2	43
1843	CMTM6 as a master regulator of PD-L1. Cancer Immunology, Immunotherapy, 2022, 71, 2325-2340.	2.0	7
1844	Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy. Frontiers in Oncology, 2022, 12, 820242.	1.3	5

#	Article	IF	Citations
1845	Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. , 2022, 136, 212761.		10
1846	Optimal Sequential Predictive Probability Designs for Early-Phase Oncology Expansion Cohorts. JCO Precision Oncology, 2022, 6, e2100390.	1.5	2
1847	Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2022, 22, 361-370.	1.1	5
1848	Increased Expression of QPRT in Breast Cancer Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration. Journal of Healthcare Engineering, 2022, 2022, 1-9.	1.1	5
1849	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clinical and Translational Oncology, 2022, 24, 1478-1491.	1.2	2
1850	Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer Discovery, 2022, 12, 1482-1499.	7.7	48
1851	Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma. Frontiers in Oncology, 2022, 12, 851628.	1.3	4
1852	Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study. Clinical Genitourinary Cancer, 2022, 20, 155-164.	0.9	10
1853	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	5.8	23
1854	Multiple roles for basement membrane proteins in cancer progression and EMT. European Journal of Cell Biology, 2022, 101, 151220.	1.6	29
1855	Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through â€œring fusionâ€•strategy. Bioorganic Chemistry, 2022, 123, 105769.	2.0	6
1856	Current methods and emerging approaches for detection of programmed death ligand 1. Biosensors and Bioelectronics, 2022, 208, 114179.	5.3	3
1857	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers, 2022, 14, 109.	1.7	21
1858	Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nature Communications, 2021, 12, 7297.	5.8	25
1859	A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy. Journal of Nanobiotechnology, 2021, 19, 434.	4.2	8
1860	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. Cancer Medicine, 2022, 11, 880-887.	1.3	5
1861	Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. Clinical Cancer Research, 2022, 28, 1363-1371.	3.2	2
1862	Expression and Prognostic Implication of PD-L1 in Patients with Urothelial Carcinoma with Variant Histology (Squamous Differentiation or Micropapillary) Undergoing Radical Cystectomy. Biomedicines, 2022, 10, 910.	1.4	2

#	Article	IF	Citations
1863	Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Critical Reviews in Oncology/Hematology, 2022, 174, 103683.	2.0	12
1865	The role of cellular proteostasis in antitumor immunity. Journal of Biological Chemistry, 2022, 298, 101930.	1.6	6
1903	JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA. Cancer Research, 2022, 82, 1789-1802.	0.4	66
1905	Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. Journal of Hematology and Oncology, 2022, 15, 45.	6.9	43
1906	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers, 2022, 14, 2241.	1.7	26
1908	Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability. Frontiers in Medicine, 2022, 9, 874213.	1.2	11
1909	Self-Assembly Catalase Nanocomplex Conveyed by Bacterial Vesicles for Oxygenated Photodynamic Therapy and Tumor Immunotherapy. International Journal of Nanomedicine, 2022, Volume 17, 1971-1985.	3.3	12
1910	Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy. Frontiers in Immunology, 2022, 13, .	2.2	5
1911	PD-L1 expression in Congolese women with triple negative breast cancer. Journal of Cancer Prevention & Current Research, 2022, 13, 61-63.	0.1	0
1912	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022, 82, 212-222.	0.9	56
1913	Development and Validation of an Immune-Related Prognostic Signature in Cervical Cancer. Frontiers in Oncology, 2022, 12, .	1.3	1
1914	CD4⁺T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
1915	The role of biomarkers in personalized immunotherapy. Biomarker Research, 2022, 10, 32.	2.8	27
1916	Detection of PD-L1â€“Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes. Journal of Immunology, 2022, 208, 2829-2836.	0.4	9
1917	Unveiling the Molecular Mechanisms Driving the Capsaicin-Induced Immunomodulatory Effects on PD-L1 Expression in Bladder and Renal Cancer Cell Lines. Cancers, 2022, 14, 2644.	1.7	6
1918	Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma. Contrast Media and Molecular Imaging, 2022, 2022, 1-9.	0.4	1
1919	Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Current Research in Immunology, 2022, 3, 118-127.	1.2	20
1920	Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Frontiers in Immunology, 0, 13, .	2.2	3

#	Article	IF	Citations
1921	Insights on recent innovations in bladder cancer immunotherapy. Cancer Cytopathology, 2022, 130, 667-683.	1.4	8
1923	Immune contexture of paediatric cancers. European Journal of Cancer, 2022, 170, 179-193.	1.3	7
1925	Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
1926	Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology, 2022, , 100936.	0.6	1
1927	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. Pharmaceuticals, 2022, 15, 747.	1.7	18
1928	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nature Reviews Drug Discovery, 2022, 21, 529-540.	21.5	134
1929	Dosing Regimens of Immune Checkpoint Inhibitors: Attempts at Lower Dose, Less Frequency, Shorter Course. Frontiers in Oncology, 0, 12, .	1.3	13
1930	Mass cytometry reveals immune atlas of urothelial carcinoma. BMC Cancer, 2022, 22, .	1.1	5
1931	Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy. Pathology Research and Practice, 2022, 236, 153990.	1.0	8
1932	Comparative Characterization of Different Molecular Formats of Bispecific Antibodies Targeting EGFR and PD-L1. Pharmaceutics, 2022, 14, 1381.	2.0	1
1933	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. Cancer, 0, , .	2.0	0
1934	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. Frontiers in Oncology, 0, 12, .	1.3	4
1935	Relationship between ATOH1 and tumor microenvironment in colon adenocarcinoma patients with different microsatellite instability status. Cancer Cell International, 2022, 22, .	1.8	3
1936	Generation, secretion and degradation of cancer immunotherapy target PD-L1. Cellular and Molecular Life Sciences, 2022, 79, .	2.4	5
1937	Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients. Frontiers in Oncology, 0, 12, .	1.3	1
1938	PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition. Frontiers in Oncology, 0, 12, .	1.3	0
1939	Integrated Urinalysis Devices Based on Interfaceâ€Engineered Fieldâ€Effect Transistor Biosensors Incorporated With Electronic Circuits. Advanced Materials, 2022, 34, .	11.1	32
1940	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. Intestinal Research, 2023, 21, 126-136.	1.0	1

#	Article	IF	Citations
1941	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers in Oncology, 0, 12, .	1.3	32
1942	Clinical studies of Atezolizumab contributing to FDA approvals. , 0, 8, 390-395.		0
1943	Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer. Clinical Cancer Research, 2022, 28, 4820-4831.	3.2	12
1945	Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Antiâ€“PD-L1 Immune Checkpoint Therapy. Journal of the National Cancer Institute, 2022, 114, 1380-1391.	3.0	4
1946	Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	6
1947	Successful treatment of advanced muscle-invasive bladder cancer with the combined therapy of toripalimab and chemotherapy: a case report. Anti-Cancer Drugs, 0, Publish Ahead of Print, .	0.7	0
1948	Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports. World Journal of Clinical Cases, 0, 10, 10550-10558.	0.3	1
1949	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. SSRN Electronic Journal, 0, , .	0.4	0
1950	Bifurcation Analysis of a Tumour-Immune Model with Nonlinear Killing Rate as State-Dependent Feedback Control. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2022, 32, .	0.7	0
1951	Prognostic value of programmed cell death ligand-1 expression in patients with bladder urothelial carcinoma undergoing radical cystectomy: A meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	1
1952	Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet, The, 2022, 400, 1712-1721.	6.3	67
1953	Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer. Frontiers in Pharmacology, 0, 13, .	1.6	4
1954	Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer. Journal of Oncology, 2022, 2022, 1-27.	0.6	4
1955	ICBatlas: A Comprehensive Resource for Depicting Immune Checkpoint Blockade Therapy Characteristics from Transcriptome Profiles. Cancer Immunology Research, 2022, 10, 1398-1406.	1.6	12
1956	Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection. Medicine (United States), 2022, 101, e30690.	0.4	0
1957	Microfluidic devices: The application in TME modeling and the potential in immunotherapy optimization. Frontiers in Genetics, 0, 13, .	1.1	4
1958	Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma â€“ Thereâ€™s room for Immune Checkpoint Blockage?. Frontiers in Immunology, 0, 13, .	2.2	4
1959	Immobilization-Free Binding and Affinity Characterization of Higher Order Bispecific Antibody Complexes Using Size-Based Microfluidics. Analytical Chemistry, 2022, 94, 13652-13658.	3.2	3

#	Article	IF	Citations
1960	APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder. Journal of Oncology, 2022, 2022, 1-12.	0.6	0
1961	TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy. , 2022, 39, .		3
1962	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
1963	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125.	1.8	11
1964	Research on the influence of APOBEC family on the occurrence, diagnosis, and treatment of various tumors. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
1965	Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor <scp>PDâ€Ł1</scp> , <scp>IDO</scp> , <scp>TIM</scp> â€ƀ, <scp>FOXP3</scp> + and <scp>CD8</scp> expressions in patients with advanced esophageal squamous cell carcinoma. Thoracic Cancer, 0, , .	0.8	1
1966	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of Hematology and Oncology, 2022, 15, .	6.9	59
1967	Immunogenic cell death mediation patterns reveal novel paradigm for characterizing the immune microenvironment and immunotherapeutic responses in bladder cancer. Frontiers in Genetics, 0, 13, .	1.1	3
1968	Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types. , 2022, 10, e005573.		11
1969	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
1971	PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way. , 2022, 10, e004590.		12
1972	Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	6
1973	Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that blocks the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. Protein Expression and Purification, 2023, 202, 106196.	0.6	2
1974	OncoTheradÂ® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5025-5036.	1.2	3
1975	A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. Journal of Translational Medicine, 2022, 20, .	1.8	4
1976	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. Medicina (Lithuania), 2022, 58, 1572.	0.8	5
1977	Photodynamic amplified immune checkpoint-blockade therapy of self-delivery bioregulator via epigenetic reprogramming. Chemical Engineering Journal, 2023, 453, 139729.	6.6	2
1978	The global research of bladder cancer immunotherapy from 2012 to 2021: A bibliometric analysis. Frontiers in Oncology, 0, 12, .	1.3	5

#	Article	IF	Citations
1979	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Aheadâ€"A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 14117.	1.8	7
1982	Urine PD-L1 is a tumor tissue candidate substitute and is associated with poor survival in muscle-invasive bladder cancer patients. International Immunopharmacology, 2023, 114, 109535.	1.7	0
1983	Stability and Hopf bifurcation of a tumorâ€"immune system interaction model with an immune checkpoint inhibitor. Communications in Nonlinear Science and Numerical Simulation, 2023, 118, 106996.	1.7	3
1984	Gallium-68â€"labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics. Clinical Cancer Research, 2023, 29, 581-591.	3.2	8
1985	Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer. Annals of Urologic Oncology, 2022, , 1-9.	0.0	1
1986	A Novel Gene Signature Associated with Inflammatory Responses and Immune Status Assists in Prognosis and Intervention for Patients with HCC. Journal of Inflammation Research, 0, Volume 15, 6729-6743.	1.6	6
1987	Integrated molecular analyses of an interferon-Î³ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification. Heliyon, 2022, 8, e12102.	1.4	0
1988	Protocol for mathematical prediction of patient response and survival to immune checkpoint inhibitor immunotherapy. STAR Protocols, 2022, 3, 101886.	0.5	0
1989	Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. Journal of Cancer Research and Clinical Oncology, 2023, 149, 5705-5715.	1.2	1
1990	Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 1291-1305.	3.3	5
1991	Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8⁺â€‰T cells in osteosarcoma. Experimental Biology and Medicine, 2023, 248, 130-145.	1.1	1
1992	Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1â€"Independent Manner. Cancer Immunology Research, 2023, 11, 241-260.	1.6	3
1993	Atezolizumab (Tecentriq) as first-line therapy in patients with metastatic urothelial carcinoma. Meditsinskiy Sovet, 2022, , 58-64.	0.1	1
1994	P. gingivalisInfection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer. Cancer Immunology Research, 2023, 11, 290-305.	1.6	3
1995	Increasing cure rates of solid tumors by immune checkpoint inhibitors. Experimental Hematology and Oncology, 2023, 12, .	2.0	17
1996	The regulation of <scp>N6</scp> â€methyladenosine modification in <scp>PDâ€L1</scp> â€induced antiâ€tumor immunity. Immunology and Cell Biology, 0, , .	1.0	2
1997	The Effects of Clonal Heterogeneity on Cancer Immunosurveillance. Annual Review of Cancer Biology, 2023, 7, 131-147.	2.3	3
1998	Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer. Urology Herald, 2023, 10, 155-164.	0.1	2

#	Article	IF	Citations
1999	YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. Nature Immunology, 2023, 24, 255-266.	7.0	31
2000	Imaging the immune cell in immunotherapy. , 2023, , 197-238.		1
2001	Role of FABP5 in T Cell Lipid Metabolism and Function in the Tumor Microenvironment. Cancers, 2023, 15, 657.	1.7	2
2002	Role of Monocyte-Derived Dendritic Cells (MoDCs) in Tumor Immune Response. , 2023, , 1-18.		0
2003	Evolving systemic management of urothelial cancers. Current Opinion in Oncology, 2023, 35, 186-199.	1.1	2
2004	Viral- and tumor-reactive natural killer cells. Seminars in Immunology, 2023, 67, 101749.	2.7	5
2005	Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma. International Immunopharmacology, 2023, 119, 110158.	1.7	2
2006	Immune Checkpoint Inhibitors in Urological Cancers. , 2023, , 1-25.		0
2007	Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma. Stem Cell Research and Therapy, 2023, 14, .	2.4	5
2008	Construction of a DDR-related signature for predicting of prognosis in metastatic colorectal carcinoma. Frontiers in Oncology, 0, 13, .	1.3	2
2010	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. Heliyon, 2023, 9, e13725.	1.4	0
2011	Optimising Cancer Immunotherapy: Challenges and Opportunities. European Medical Journal (Chelmsford, England), 0, , 26-43.	3.0	0
2012	Regulation of programmed death ligand 1 expression by interferonâ€Î³ and tumour necrosis factorâ€Î± in canine tumour cell lines. Veterinary and Comparative Oncology, 0, , .	0.8	0
2013	Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. Journal of Clinical Oncology, 2023, 41, 3122-3134.	0.8	20
2016	Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer. BMC Cancer, 2023, 23, .	1.1	1
2017	Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein. Journal of Biomolecular Structure and Dynamics, 2023, 41, 14771-14785.	2.0	1
2018	Sequence Variants in PSMB8/PSMB9 Immunoproteasome Genes and Risk of Urothelial Bladder Carcinoma. Cureus, 2023, , .	0.2	0
2019	Generation of robust bispecific antibodies through fusion of single-domain antibodies on IgG scaffolds: a comprehensive comparison of formats. MAbs, 2023, 15, .	2.6	4

#	Article	IF	Citations
2020	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
2021	Programmed Cell Death 1 checkpoint inhibitors as cancer therapies. , 0, 36, 8-16.		0
2022	The usage of Pembrolizumab in Metastatic Urothelial Carcinoma. , 0, 36, 331-340.		0
2023	Identifying novel biomarkers associated with bladder cancer treatment outcomes. Frontiers in Oncology, 0, 13, .	1.3	5
2024	Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. Human Genomics, 2023, 17, .	1.4	1
2025	GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data. Frontiers in Oncology, 0, 13, .	1.3	0
2026	Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. Immunotherapy, 2023, 15, 631-639.	1.0	2
2027	Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer. PeerJ, 0, 11, e15088.	0.9	0
2028	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. Healthcare (Switzerland), 2023, 11, 1073.	1.0	0
2029	Single-Cell RNA Sequencing Reveals Cellular Heterogeneity in an Acral Amelanotic Melanoma After Immunotherapy Treatment. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 16, 1009-1018.	0.8	0
2030	Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis. Frontiers in Oncology, 0, 13, .	1.3	0
2031	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
2034	Editorial: Tumor microenvironment in bladder cancer. Frontiers in Oncology, 0, 13, .	1.3	0
2041	Local Î³Î´ T cells: translating promise to practice in cancer immunotherapy. British Journal of Cancer, 2023, 129, 393-405.	2.9	4
2055	From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 0, , .	1.9	2
2078	Natural cationic polymer-derived injectable hydrogels for targeted chemotherapy. Materials Advances, 2023, 4, 6064-6091.	2.6	1
2080	Progress in systemic therapy for advanced-stage urothelial carcinoma. Nature Reviews Clinical Oncology, 2024, 21, 8-27.	12.5	1
2091	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. British Journal of Cancer, 2023, 129, 1409-1416.	2.9	4

#	Article	IF	Citations
2093	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. Cancer Treatment and Research, 2023, , 49-94.	0.2	0
2099	THE EFFECT OF IMMUNOLOGICAL BIOMARKERS - NLR, PLR, LMR, PD-L1 ON THE SURVIVAL OF PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER. , 0, , .		0
2101	Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nature Reviews Clinical Oncology, 2024, 21, 257-277.	12.5	1